Association of an Anti-inflammatory Cytokine Gene IL4 Polymorphism with the Risk of Type 2 Diabetes Mellitus in Korean Populations.
('Association', 'Association', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('Anti-inflammatory', 'Anti-inflammatory', 'JJ', 'I-NP', 'O')
('Cytokine', 'Cytokine', 'NN', 'I-NP', 'O')
('Gene', 'Gene', 'NN', 'I-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'O')
('Polymorphism', 'Polymorphism', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Risk', 'Risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Type', 'Type', 'NN', 'B-NP', 'O')
('2', '2', 'CD', 'I-NP', 'O')
('Diabetes', 'Diabetes', 'NNP', 'I-NP', 'O')
('Mellitus', 'Mellitus', 'NNP', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'NNP', 'B-NP', 'O')
('Populations.', 'Populations.', 'NNP', 'I-NP', 'O')
Chronic inflammation has been implicated as one of the important etiological factors in insulin resistance and type 2 diabetes mellitus (T2DM).
('Chronic', 'Chronic', 'JJ', 'B-NP', 'O')
('inflammation', 'inflammation', 'NN', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('implicated', 'implicate', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('one', 'one', 'CD', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('important', 'important', 'JJ', 'I-NP', 'O')
('etiological', 'etiological', 'JJ', 'I-NP', 'B-protein')
('factors', 'factor', 'NNS', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('insulin', 'insulin', 'NN', 'B-NP', 'O')
('resistance', 'resistance', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('type', 'type', 'NN', 'B-NP', 'O')
('2', '2', 'CD', 'I-NP', 'O')
('diabetes', 'diabetes', 'NN', 'I-NP', 'O')
('mellitus', 'mellitus', 'NN', 'I-NP', 'O')
('(T2DM).', '(T2DM).', 'NN', 'I-NP', 'O')
To investigate the role of anti-inflammatory cytokines in the development of T2DM, we conducted a case-control study to assess the association between IL4/IL4R polymorphisms and disease risk.
('To', 'To', 'TO', 'B-VP', 'O')
('investigate', 'investigate', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('anti-inflammatory', 'anti-inflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('development', 'development', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('T2DM,', 'T2DM,', 'NN', 'B-NP', 'B-protein')
('we', 'we', 'PRP', 'B-NP', 'O')
('conducted', 'conduct', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('case-control', 'case-control', 'JJ', 'I-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('assess', 'assess', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('IL4/IL4R', 'IL4/IL4R', 'NN', 'B-NP', 'B-DNA')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('disease', 'disease', 'NN', 'B-NP', 'O')
('risk.', 'risk.', 'NN', 'I-NP', 'O')
We firstly identified single nucleotide polymorphisms (SNP) at IL4 and IL4RA loci by sequencing the loci in Korean participants.
('We', 'We', 'PRP', 'B-NP', 'O')
('firstly', 'firstly', 'RB', 'B-ADVP', 'O')
('identified', 'identify', 'VBD', 'B-VP', 'O')
('single', 'single', 'JJ', 'B-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('(SNP)', '(SNP)', 'NN', 'I-NP', 'B-protein')
('at', 'at', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4RA', 'IL4RA', 'NN', 'I-NP', 'B-protein')
('loci', 'locus', 'NNS', 'I-NP', 'I-protein')
('by', 'by', 'IN', 'B-PP', 'O')
('sequencing', 'sequence', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('loci', 'locus', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('participants.', 'participants.', 'NNS', 'I-NP', 'O')
Case-control studies were conducted by genotyping the SNPs in 474 T2DM cases and 470 non-diabetic controls recruited from community-based cohorts.
('Case-control', 'Case-control', 'JJ', 'B-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('conducted', 'conduct', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('genotyping', 'genotype', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNPs', 'SNP', 'NNS', 'I-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('474', '474', 'CD', 'B-NP', 'O')
('T2DM', 'T2DM', 'NN', 'I-NP', 'O')
('cases', 'case', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('470', '470', 'CD', 'B-NP', 'O')
('non-diabetic', 'non-diabetic', 'JJ', 'I-NP', 'O')
('controls', 'control', 'NNS', 'I-NP', 'O')
('recruited', 'recruit', 'VBN', 'B-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('community-based', 'community-based', 'JJ', 'B-NP', 'O')
('cohorts.', 'cohorts.', 'NNS', 'I-NP', 'O')
Replication of the associated signals was performed in 1,216 cases and 1,352 controls.
('Replication', 'Replication', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('associated', 'associate', 'VBN', 'I-NP', 'O')
('signals', 'signal', 'NNS', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('performed', 'perform', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('1,216', '1,216', 'CD', 'B-NP', 'O')
('cases', 'case', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('1,352', '1,352', 'CD', 'B-NP', 'O')
('controls.', 'controls.', 'NNS', 'I-NP', 'O')
We assessed effect of IL4-IL4RA interaction on T2DM using logistic regression method.
('We', 'We', 'PRP', 'B-NP', 'O')
('assessed', 'assess', 'VBD', 'B-VP', 'O')
('effect', 'effect', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4-IL4RA', 'IL4-IL4RA', 'NN', 'B-NP', 'O')
('interaction', 'interaction', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('logistic', 'logistic', 'JJ', 'B-NP', 'O')
('regression', 'regression', 'NN', 'I-NP', 'O')
('method.', 'method.', 'NN', 'I-NP', 'O')
The functional relevance of the SNP associated with disease risk was determined using a reporter expression assay.
('The', 'The', 'DT', 'B-NP', 'O')
('functional', 'functional', 'JJ', 'I-NP', 'O')
('relevance', 'relevance', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNP', 'SNP', 'NN', 'I-NP', 'B-protein')
('associated', 'associate', 'VBN', 'B-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('disease', 'disease', 'NN', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('determined', 'determine', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('assay.', 'assay.', 'NN', 'I-NP', 'O')
We identified a strong association between the IL4 promoter variant rs2243250 and T2DM risk (OR=0.77; 95% CI, 0.67∼0.88; p=1.65×10－4 in the meta-analysis).
('We', 'We', 'PRP', 'B-NP', 'O')
('identified', 'identify', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('strong', 'strong', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-DNA')
('promoter', 'promoter', 'NN', 'I-NP', 'I-DNA')
('variant', 'variant', 'JJ', 'I-NP', 'O')
('rs2243250', 'rs2243250', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('T2DM', 'T2DM', 'NN', 'I-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('(OR=0.77;', '(OR=0.77;', 'NN', 'I-NP', 'O')
('95%', '95%', 'CD', 'B-NP', 'O')
('CI,', 'CI,', 'NN', 'I-NP', 'O')
('0.67∼0.88;', '0.67∼0.88;', 'CD', 'B-NP', 'O')
('p=1.65×10－4', 'p=1.65×10－4', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('meta-analysis).', 'meta-analysis).', 'NN', 'I-NP', 'O')
The reporter gene expression assay demonstrated that the presence of rs2243250 might affect the gene expression level with ∼1.5-fold allele difference.
('The', 'The', 'DT', 'B-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('expression', 'expression', 'NN', 'I-NP', 'O')
('assay', 'assay', 'NN', 'I-NP', 'O')
('demonstrated', 'demonstrate', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('presence', 'presence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('rs2243250', 'rs2243250', 'NN', 'B-NP', 'O')
('might', 'might', 'MD', 'B-VP', 'O')
('affect', 'affect', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('level', 'level', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('∼1.5-fold', '∼1.5-fold', 'JJ', 'B-NP', 'B-DNA')
('allele', 'allele', 'NN', 'I-NP', 'I-DNA')
('difference.', 'difference.', '.', 'O', 'O')
Our findings contribute to the identification of IL4 as a T2D susceptibility locus, further supporting the role of antiinflammatory cytokines in T2DM disease development.
('Our', 'Our', 'PRP$', 'B-NP', 'O')
('findings', 'finding', 'NNS', 'I-NP', 'O')
('contribute', 'contribute', 'VBP', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('identification', 'identification', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('T2D', 'T2D', 'NN', 'I-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('locus,', 'locus,', 'NN', 'I-NP', 'O')
('further', 'further', 'RB', 'B-VP', 'O')
('supporting', 'support', 'VBG', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('disease', 'disease', 'NN', 'I-NP', 'O')
('development.', 'development.', 'NN', 'I-NP', 'O')
Type 2 diabetes mellitus (T2DM) is one of the diseases for which the etiological factors have been revealed by recent progress in genomewide association studies (GWAS).
('Type', 'Type', 'NN', 'B-NP', 'O')
('2', '2', 'CD', 'I-NP', 'O')
('diabetes', 'diabetes', 'NN', 'I-NP', 'O')
('mellitus', 'mellitus', 'NN', 'I-NP', 'O')
('(T2DM)', '(T2DM)', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('one', 'one', 'CD', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('diseases', 'disease', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('etiological', 'etiological', 'JJ', 'I-NP', 'B-protein')
('factors', 'factor', 'NNS', 'I-NP', 'I-protein')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('revealed', 'reveal', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('recent', 'recent', 'JJ', 'B-NP', 'O')
('progress', 'progress', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('genomewide', 'genomewide', 'JJ', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('(GWAS).', '(GWAS).', 'NNP', 'B-NP', 'O')
More than 20 genetic loci have been identified as being associated with the risk of T2DM, and this finding has been replicated across different ethnic populations.
('More', 'More', 'JJR', 'B-NP', 'O')
('than', 'than', 'IN', 'I-NP', 'O')
('20', '20', 'CD', 'I-NP', 'B-DNA')
('genetic', 'genetic', 'JJ', 'I-NP', 'I-DNA')
('loci', 'locus', 'NNS', 'I-NP', 'I-DNA')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('identified', 'identify', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('being', 'be', 'VBG', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('T2DM,', 'T2DM,', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('finding', 'finding', 'NN', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('replicated', 'replicate', 'VBN', 'I-VP', 'O')
('across', 'across', 'IN', 'B-PP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('populations.', 'populations.', 'NN', 'I-NP', 'O')
Many of the loci are involved in pancreatic β cell function, suggesting the technical validity of GWAS and predominant contribution of these loci to T2DM (Prokopenko et al., 2008).
('Many', 'Many', 'JJ', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('loci', 'locus', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('involved', 'involve', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('pancreatic', 'pancreatic', 'JJ', 'B-NP', 'O')
('β', 'β', 'NN', 'I-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('function,', 'function,', 'NN', 'I-NP', 'O')
('suggesting', 'suggest', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('technical', 'technical', 'JJ', 'I-NP', 'O')
('validity', 'validity', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('GWAS', 'GWAS', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('predominant', 'predominant', 'JJ', 'B-NP', 'O')
('contribution', 'contribution', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('these', 'these', 'DT', 'B-NP', 'O')
('loci', 'locus', 'NNS', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('(Prokopenko', '(Prokopenko', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2008).', '2008).', 'CD', 'B-NP', 'O')
However, given the genetic heterogeneity of the disease, hypothesisbased candidate gene approaches have been successfully applied along with GWAS to identify additional loci that are moderately associated with T2DM.
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('given', 'give', 'VBN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genetic', 'genetic', 'JJ', 'I-NP', 'O')
('heterogeneity', 'heterogeneity', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('disease,', 'disease,', 'NN', 'I-NP', 'O')
('hypothesisbased', 'hypothesisbased', 'JJ', 'I-NP', 'O')
('candidate', 'candidate', 'NN', 'I-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('approaches', 'approach', 'NNS', 'I-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('successfully', 'successfully', 'RB', 'I-VP', 'O')
('applied', 'apply', 'VBN', 'I-VP', 'O')
('along', 'along', 'IN', 'B-PP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('GWAS', 'GWAS', 'NN', 'B-NP', 'B-protein')
('to', 'to', 'TO', 'B-VP', 'O')
('identify', 'identify', 'VB', 'I-VP', 'O')
('additional', 'additional', 'JJ', 'B-NP', 'O')
('loci', 'locus', 'NNS', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('moderately', 'moderately', 'RB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('T2DM.', 'T2DM.', 'NN', 'B-NP', 'O')
Among the candidates, genes involved in inflammation have been intensively studied, with most studies examining the role of subclinical chronic inflammation in the development of insulin resistance and T2DM (Shoelson et al., 2007).
('Among', 'Among', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('candidates,', 'candidates,', 'NN', 'I-NP', 'B-DNA')
('genes', 'gene', 'NNS', 'I-NP', 'I-DNA')
('involved', 'involve', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('inflammation', 'inflammation', 'NN', 'B-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('intensively', 'intensively', 'RB', 'I-VP', 'O')
('studied,', 'studied,', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('most', 'most', 'JJS', 'B-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('examining', 'examine', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('subclinical', 'subclinical', 'JJ', 'B-NP', 'O')
('chronic', 'chronic', 'JJ', 'I-NP', 'O')
('inflammation', 'inflammation', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('development', 'development', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('insulin', 'insulin', 'NN', 'B-NP', 'O')
('resistance', 'resistance', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('(Shoelson', '(Shoelson', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2007).', '2007).', 'CD', 'B-NP', 'O')
It is known that chronic overnutrition results in local inflammation in adipose tissue, mediated by macrophage infiltration and increased production of proinflammatory mediators, the occurrence of which potentiates insulin resistance (Weisberg et al., 2003).
('It', 'It', 'PRP', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('known', 'know', 'VBN', 'I-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('chronic', 'chronic', 'JJ', 'B-NP', 'O')
('overnutrition', 'overnutrition', 'NN', 'I-NP', 'O')
('results', 'result', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('local', 'local', 'JJ', 'B-NP', 'O')
('inflammation', 'inflammation', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('adipose', 'adipose', 'NN', 'B-NP', 'O')
('tissue,', 'tissue,', 'NN', 'I-NP', 'O')
('mediated', 'mediate', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('macrophage', 'macrophage', 'NN', 'B-NP', 'O')
('infiltration', 'infiltration', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('increased', 'increase', 'VBN', 'B-NP', 'O')
('production', 'production', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('proinflammatory', 'proinflammatory', 'JJ', 'B-NP', 'O')
('mediators,', 'mediators,', 'NN', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('occurrence', 'occurrence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('potentiates', 'potentiate', 'VBZ', 'B-VP', 'O')
('insulin', 'insulin', 'NN', 'B-NP', 'B-protein')
('resistance', 'resistance', 'NN', 'I-NP', 'I-protein')
('(Weisberg', '(Weisberg', 'NNP', 'I-NP', 'I-protein')
('et', 'et', 'NNP', 'I-NP', 'I-protein')
('al.,', 'al.,', 'IN', 'B-PP', 'I-protein')
('2003).', '2003).', 'CD', 'B-NP', 'I-protein')
Consistently, genetic variants in proinflammatory markers and cytokines have been tested in many studies, supported by clinical observation including elevated levels of tumor necrosis factorα (TNFα), Creactive protein (CRP) and interleukin6 (IL6) in patients with obesityrelated insulin resistance (Genco et al., 2005; Plomgaard et al., 2005; Pradhan et al., 2001).
('Consistently,', 'Consistently,', 'IN', 'B-PP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('variants', 'variant', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('proinflammatory', 'proinflammatory', 'JJ', 'B-NP', 'B-protein')
('markers', 'marker', 'NNS', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'B-protein')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('tested', 'test', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('many', 'many', 'JJ', 'B-NP', 'O')
('studies,', 'studies,', 'NN', 'I-NP', 'O')
('supported', 'support', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('clinical', 'clinical', 'JJ', 'B-NP', 'O')
('observation', 'observation', 'NN', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('elevated', 'elevated', 'JJ', 'B-NP', 'O')
('levels', 'level', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('tumor', 'tumor', 'NN', 'B-NP', 'B-protein')
('necrosis', 'necrosis', 'NN', 'I-NP', 'I-protein')
('factorα', 'factorα', 'NN', 'I-NP', 'I-protein')
('(TNFα),', '(TNFα),', 'NN', 'I-NP', 'I-protein')
('Creactive', 'Creactive', 'JJ', 'I-NP', 'I-protein')
('protein', 'protein', 'NN', 'I-NP', 'I-protein')
('(CRP)', '(CRP)', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('interleukin6', 'interleukin6', 'NN', 'B-NP', 'B-protein')
('(IL6)', '(IL6)', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('patients', 'patient', 'NNS', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('obesityrelated', 'obesityrelate', 'VBN', 'B-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'B-protein')
('resistance', 'resistance', 'NN', 'I-NP', 'I-protein')
('(Genco', '(Genco', 'NNP', 'I-NP', 'I-protein')
('et', 'et', 'NNP', 'I-NP', 'I-protein')
('al.,', 'al.,', 'VBD', 'B-VP', 'I-protein')
('2005;', '2005;', ':', 'O', 'I-protein')
('Plomgaard', 'Plomgaard', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2005;', '2005;', ':', 'O', 'O')
('Pradhan', 'Pradhan', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2001).', '2001).', 'CD', 'B-NP', 'O')
Based on the identification of homeostatic regulatory mechanisms in the inflammatory system that involve both pro and antiinflammatory cytokines, it has been proposed that antiinflammatory cytokines, such as insulinlike growth factor1 (IGF1), IL10, IL13 and IL4, play a role in the pathogenesis of insulin resistance and T2DM.
('Based', 'Base', 'VBN', 'B-PP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('identification', 'identification', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('homeostatic', 'homeostatic', 'JJ', 'B-NP', 'O')
('regulatory', 'regulatory', 'JJ', 'I-NP', 'O')
('mechanisms', 'mechanism', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('inflammatory', 'inflammatory', 'JJ', 'I-NP', 'O')
('system', 'system', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('involve', 'involve', 'VBP', 'B-VP', 'O')
('both', 'both', 'CC', 'O', 'O')
('pro', 'pro', 'JJ', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'I-NP', 'O')
('cytokines,', 'cytokines,', 'NN', 'I-NP', 'O')
('it', 'it', 'PRP', 'B-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('proposed', 'propose', 'VBN', 'I-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines,', 'cytokines,', 'NN', 'I-NP', 'I-protein')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('insulinlike', 'insulinlike', 'JJ', 'B-NP', 'B-protein')
('growth', 'growth', 'NN', 'I-NP', 'I-protein')
('factor1', 'factor1', 'NN', 'I-NP', 'I-protein')
('(IGF1),', '(IGF1),', 'NN', 'I-NP', 'O')
('IL10,', 'IL10,', 'NN', 'I-NP', 'O')
('IL13', 'IL13', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4,', 'IL4,', 'NN', 'I-NP', 'B-protein')
('play', 'play', 'VBP', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('pathogenesis', 'pathogenesis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('insulin', 'insulin', 'NN', 'B-NP', 'B-protein')
('resistance', 'resistance', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('T2DM.', 'T2DM.', 'NN', 'B-NP', 'O')
However, the underlying mechanism of their disrupted functions in chronic inflammation in relation to T2DM remains to be defined.
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('underlying', 'underlie', 'VBG', 'I-NP', 'O')
('mechanism', 'mechanism', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('disrupted', 'disrupt', 'VBN', 'I-NP', 'O')
('functions', 'function', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('chronic', 'chronic', 'JJ', 'B-NP', 'O')
('inflammation', 'inflammation', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('relation', 'relation', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'B-protein')
('remains', 'remain', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('defined.', 'defined.', 'VBN', 'I-VP', 'O')
Interestingly, there has been a report showing disruption of antiinflammatory responses in type 2 diabetic model animals, suggesting a role of antiinflammatory processes in T2DM (O'Connor et al., 2007).
('Interestingly,', 'Interestingly,', 'IN', 'B-SBAR', 'O')
('there', 'there', 'EX', 'B-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('report', 'report', 'NN', 'I-NP', 'O')
('showing', 'show', 'VBG', 'B-VP', 'O')
('disruption', 'disruption', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'B-NP', 'O')
('responses', 'response', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('type', 'type', 'NN', 'B-NP', 'O')
('2', '2', 'CD', 'I-NP', 'O')
('diabetic', 'diabetic', 'JJ', 'I-NP', 'O')
('model', 'model', 'NN', 'I-NP', 'O')
('animals,', 'animals,', 'NN', 'I-NP', 'O')
('suggesting', 'suggest', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'B-NP', 'O')
('processes', 'process', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
("(O'Connor", "(O'Connor", 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2007).', '2007).', 'CD', 'B-NP', 'O')
To investigate the implication of anti-inflammatory cytokines in the development of T2DM, we conducted case-control association studies to examine the correlation between disease risk and single nucleotide polymorphisms (SNP) in the relevant genetic loci including IL4 and the IL4 receptor-coding gene, IL4RA, which express an anti-inflammatory cytokine and its receptor that play a key role in directing macrophages to an 'alternatively activated' state that is characterized by low expression patterns of pro-inflammatory cytokines and high levels of anti-inflammatory cytokines (Gordon, 2003).
('To', 'To', 'TO', 'B-VP', 'O')
('investigate', 'investigate', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('implication', 'implication', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('anti-inflammatory', 'anti-inflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('development', 'development', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('T2DM,', 'T2DM,', 'NN', 'B-NP', 'B-protein')
('we', 'we', 'PRP', 'B-NP', 'O')
('conducted', 'conduct', 'VBD', 'B-VP', 'O')
('case-control', 'case-control', 'JJ', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('examine', 'examine', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('correlation', 'correlation', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('disease', 'disease', 'NN', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('single', 'single', 'JJ', 'B-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('(SNP)', '(SNP)', 'NN', 'I-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('relevant', 'relevant', 'JJ', 'I-NP', 'O')
('genetic', 'genetic', 'JJ', 'I-NP', 'O')
('loci', 'locus', 'NNS', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('receptor-coding', 'receptor-coding', 'JJ', 'I-NP', 'O')
('gene,', 'gene,', 'NN', 'I-NP', 'O')
('IL4RA,', 'IL4RA,', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('express', 'express', 'VBP', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('anti-inflammatory', 'anti-inflammatory', 'JJ', 'I-NP', 'B-protein')
('cytokine', 'cytokine', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
('receptor', 'receptor', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('play', 'play', 'VBP', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('key', 'key', 'JJ', 'I-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('directing', 'direct', 'VBG', 'B-VP', 'O')
('macrophages', 'macrophage', 'NNS', 'B-NP', 'B-cell_type')
('to', 'to', 'TO', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
("'alternatively", "'alternatively", 'RB', 'I-NP', 'O')
("activated'", "activated'", 'JJ', 'I-NP', 'O')
('state', 'state', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('characterized', 'characterize', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('low', 'low', 'JJ', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('patterns', 'pattern', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('pro-inflammatory', 'pro-inflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('high', 'high', 'JJ', 'B-NP', 'O')
('levels', 'level', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('anti-inflammatory', 'anti-inflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('(Gordon,', '(Gordon,', 'IN', 'B-PP', 'O')
('2003).', '2003).', 'CD', 'B-NP', 'O')
Our findings indicate that a promoter variant of an anti-inflammatory cytokine IL4 gene is associated with risk of T2DM in the Korean population, which, we believe, lends significant insight into the role of antiinflammatory cytokines in the T2DM etiology.
('Our', 'Our', 'PRP$', 'B-NP', 'O')
('findings', 'finding', 'NNS', 'I-NP', 'O')
('indicate', 'indicate', 'VBP', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('promoter', 'promoter', 'NN', 'I-NP', 'O')
('variant', 'variant', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('anti-inflammatory', 'anti-inflammatory', 'JJ', 'I-NP', 'B-protein')
('cytokine', 'cytokine', 'NN', 'I-NP', 'I-protein')
('IL4', 'IL4', 'NN', 'I-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('risk', 'risk', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'O')
('population,', 'population,', 'NN', 'I-NP', 'O')
('which,', 'which,', 'IN', 'B-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('believe,', 'believe,', 'VBP', 'B-VP', 'O')
('lends', 'lend', 'VBZ', 'B-VP', 'O')
('significant', 'significant', 'JJ', 'B-NP', 'O')
('insight', 'insight', 'NN', 'I-NP', 'O')
('into', 'into', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('T2DM', 'T2DM', 'NN', 'I-NP', 'O')
('etiology.', 'etiology.', 'FW', 'B-NP', 'O')
Study subjects for SNP discovery and the first and second stages of association analyses were recruited from two community-based cohorts established as part of the Korean Genome and Epidemiology Study (KoGES) conducted by Korea Centers for Disease Control and Prevention (KCDC).
('Study', 'Study', 'JJ', 'B-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('SNP', 'SNP', 'NN', 'B-NP', 'O')
('discovery', 'discovery', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('first', 'first', 'JJ', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('second', 'second', 'JJ', 'I-NP', 'O')
('stages', 'stage', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('association', 'association', 'NN', 'B-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('recruited', 'recruit', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('two', 'two', 'CD', 'B-NP', 'O')
('community-based', 'community-based', 'JJ', 'I-NP', 'O')
('cohorts', 'cohort', 'NNS', 'I-NP', 'O')
('established', 'establish', 'VBN', 'B-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('part', 'part', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'B-DNA')
('Genome', 'Genome', 'NNP', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'I-NP', 'O')
('Epidemiology', 'Epidemiology', 'NNP', 'I-NP', 'O')
('Study', 'Study', 'NNP', 'I-NP', 'O')
('(KoGES)', '(KoGES)', 'NNP', 'I-NP', 'O')
('conducted', 'conduct', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('Korea', 'Korea', 'NNP', 'B-NP', 'O')
('Centers', 'Center', 'NNPS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('Disease', 'Disease', 'NNP', 'B-NP', 'O')
('Control', 'Control', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Prevention', 'Prevention', 'NNP', 'B-NP', 'O')
('(KCDC).', '(KCDC).', 'NNP', 'I-NP', 'O')
The Institutional Review Board of KCDC approved the study, and informed consent was obtained from every subject prior to enrollment.
('The', 'The', 'DT', 'B-NP', 'O')
('Institutional', 'Institutional', 'NNP', 'I-NP', 'O')
('Review', 'Review', 'NNP', 'I-NP', 'O')
('Board', 'Board', 'NNP', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('KCDC', 'KCDC', 'NNP', 'B-NP', 'B-cell_type')
('approved', 'approve', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('study,', 'study,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('informed', 'inform', 'VBN', 'B-NP', 'O')
('consent', 'consent', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('obtained', 'obtain', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('every', 'every', 'DT', 'B-NP', 'O')
('subject', 'subject', 'NN', 'I-NP', 'O')
('prior', 'prior', 'RB', 'B-ADVP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('enrollment.', 'enrollment.', 'VB', 'I-VP', 'O')
The case subjects with T2DM were selected in accordance with the 1999 World Health Organization criterion.
('The', 'The', 'DT', 'B-NP', 'O')
('case', 'case', 'NN', 'I-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('selected', 'select', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('accordance', 'accordance', 'NN', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('1999', '1999', 'CD', 'I-NP', 'O')
('World', 'World', 'NNP', 'I-NP', 'O')
('Health', 'Health', 'NNP', 'I-NP', 'O')
('Organization', 'Organization', 'NNP', 'I-NP', 'O')
('criterion.', 'criterion.', 'NN', 'I-NP', 'O')
Control subjects were composed of individuals with no history of diabetes or firstdegree relatives with diabetes, a fasting plasma glucose level≤126 mg/dL and a plasma glucose level≤140 mg/dL 120 min after glucose ingestion.
('Control', 'Control', 'NN', 'B-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('composed', 'compose', 'VBN', 'I-VP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('individuals', 'individual', 'NNS', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('history', 'history', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('diabetes', 'diabetes', 'NN', 'B-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('firstdegree', 'firstdegree', 'NN', 'I-NP', 'O')
('relatives', 'relative', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('diabetes,', 'diabetes,', 'NN', 'B-NP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('fasting', 'fast', 'VBG', 'I-NP', 'O')
('plasma', 'plasma', 'NN', 'I-NP', 'O')
('glucose', 'glucose', 'NN', 'I-NP', 'O')
('level≤126', 'level≤126', 'NN', 'I-NP', 'O')
('mg/dL', 'mg/dL', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('plasma', 'plasma', 'NN', 'I-NP', 'O')
('glucose', 'glucose', 'NN', 'I-NP', 'O')
('level≤140', 'level≤140', 'NN', 'I-NP', 'O')
('mg/dL', 'mg/dL', 'NN', 'I-NP', 'O')
('120', '120', 'CD', 'I-NP', 'O')
('min', 'min', 'NN', 'I-NP', 'O')
('after', 'after', 'IN', 'B-PP', 'O')
('glucose', 'glucose', 'NN', 'B-NP', 'O')
('ingestion.', 'ingestion.', 'NN', 'I-NP', 'O')
The parameters measured were height, weight, waist and hip circumference and blood pressure.
('The', 'The', 'DT', 'B-NP', 'O')
('parameters', 'parameter', 'NNS', 'I-NP', 'O')
('measured', 'measure', 'VBN', 'B-VP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('height,', 'height,', 'JJ', 'B-NP', 'O')
('weight,', 'weight,', 'NN', 'I-NP', 'O')
('waist', 'waist', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('hip', 'hip', 'NN', 'B-NP', 'O')
('circumference', 'circumference', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('blood', 'blood', 'NN', 'B-NP', 'O')
('pressure.', 'pressure.', 'NN', 'I-NP', 'O')
Body mass index (BMI) was calculated by dividing weight (kg) by height squared (m2).
('Body', 'Body', 'JJ', 'B-NP', 'O')
('mass', 'mass', 'NN', 'I-NP', 'O')
('index', 'index', 'NN', 'I-NP', 'O')
('(BMI)', '(BMI)', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('calculated', 'calculate', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('dividing', 'divide', 'VBG', 'B-VP', 'O')
('weight', 'weight', 'NN', 'B-NP', 'O')
('(kg)', '(kg)', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('height', 'height', 'NN', 'B-NP', 'O')
('squared', 'square', 'VBD', 'B-VP', 'O')
('(m2).', '(m2).', 'LS', 'B-LST', 'O')
Waisttohip ratio (WHR) was calculated from these measurements.
('Waisttohip', 'Waisttohip', 'NN', 'B-NP', 'O')
('ratio', 'ratio', 'NN', 'I-NP', 'O')
('(WHR)', '(WHR)', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('calculated', 'calculate', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('these', 'these', 'DT', 'B-NP', 'O')
('measurements.', 'measurements.', 'NN', 'I-NP', 'O')
Blood samples were collected at three separate times (0, 60, 120 min) from the cohort participants who were subjected to oral glucose tolerance tests (OGTT) and analyzed for glucose and insulin concentration at the given time.
('Blood', 'Blood', 'NN', 'B-NP', 'O')
('samples', 'sample', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('collected', 'collect', 'VBN', 'I-VP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('three', 'three', 'CD', 'B-NP', 'O')
('separate', 'separate', 'JJ', 'I-NP', 'O')
('times', 'time', 'NNS', 'I-NP', 'O')
('(0,', '(0,', 'NN', 'I-NP', 'O')
('60,', '60,', 'VBD', 'B-VP', 'O')
('120', '120', 'CD', 'B-NP', 'O')
('min)', 'min)', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cohort', 'cohort', 'JJ', 'I-NP', 'O')
('participants', 'participant', 'NNS', 'I-NP', 'O')
('who', 'who', 'WP', 'B-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('subjected', 'subject', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('oral', 'oral', 'JJ', 'B-NP', 'O')
('glucose', 'glucose', 'NN', 'I-NP', 'O')
('tolerance', 'tolerance', 'NN', 'I-NP', 'O')
('tests', 'test', 'NNS', 'I-NP', 'O')
('(OGTT)', '(OGTT)', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('analyzed', 'analyze', 'VBN', 'B-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('glucose', 'glucose', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'B-protein')
('concentration', 'concentration', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('given', 'give', 'VBN', 'I-NP', 'O')
('time.', 'time.', 'NN', 'I-NP', 'O')
Cholesterol, triglyceride, and highdensity lipoprotein (HDL) cholesterol were measured at baseline.
('Cholesterol,', 'Cholesterol,', 'NN', 'B-NP', 'O')
('triglyceride,', 'triglyceride,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('highdensity', 'highdensity', 'NN', 'B-NP', 'O')
('lipoprotein', 'lipoprotein', 'NN', 'I-NP', 'O')
('(HDL)', '(HDL)', 'NN', 'I-NP', 'O')
('cholesterol', 'cholesterol', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('measured', 'measure', 'VBN', 'I-VP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('baseline.', 'baseline.', 'NN', 'B-NP', 'O')
Lowdensity lipoprotein (LDL) cholesterol level was calculated using the Friedewald formula for subjects with a triglyceride level less than 400 mg/dL (LDL=total cholesterol－(triglyceride/ 5+HDL)).
('Lowdensity', 'Lowdensity', 'NN', 'B-NP', 'B-protein')
('lipoprotein', 'lipoprotein', 'NN', 'I-NP', 'I-protein')
('(LDL)', '(LDL)', 'NN', 'I-NP', 'O')
('cholesterol', 'cholesterol', 'NN', 'I-NP', 'O')
('level', 'level', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('calculated', 'calculate', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Friedewald', 'Friedewald', 'NNP', 'I-NP', 'O')
('formula', 'formula', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('subjects', 'subject', 'NNS', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('triglyceride', 'triglyceride', 'NN', 'I-NP', 'O')
('level', 'level', 'NN', 'I-NP', 'O')
('less', 'less', 'JJR', 'B-NP', 'O')
('than', 'than', 'IN', 'I-NP', 'O')
('400', '400', 'CD', 'I-NP', 'O')
('mg/dL', 'mg/dL', 'NN', 'I-NP', 'O')
('(LDL=total', '(LDL=total', 'JJ', 'I-NP', 'O')
('cholesterol－(triglyceride/', 'cholesterol－(triglyceride/', 'NN', 'I-NP', 'O')
('5+HDL)).', '5+HDL)).', '.', 'O', 'O')
Clinical parameters of the study subjects are summarized in Table 1.
('Clinical', 'Clinical', 'JJ', 'B-NP', 'O')
('parameters', 'parameter', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('summarized', 'summarize', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Table', 'Table', 'JJ', 'B-NP', 'O')
('1.', '1.', 'CD', 'I-NP', 'O')
To identify SNPs of IL4 and IL4RA, we sequenced entire exons of the genes including the coding and the 5’ and 3’untranslated regions (up to approximately 2 kb upstream of the start codon and 0.5 kb downstream of the stop codon) as well as exonintron boundary regions using genomic DNA samples collected from 24 unrelated Korean subjects.
('To', 'To', 'TO', 'B-VP', 'O')
('identify', 'identify', 'VB', 'I-VP', 'O')
('SNPs', 'SNP', 'NNS', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4RA,', 'IL4RA,', 'NN', 'I-NP', 'B-protein')
('we', 'we', 'PRP', 'B-NP', 'O')
('sequenced', 'sequence', 'VBD', 'B-VP', 'O')
('entire', 'entire', 'JJ', 'B-NP', 'O')
('exons', 'exon', 'NNS', 'I-NP', 'B-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genes', 'gene', 'NNS', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('coding', 'coding', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('5’', '5’', 'NN', 'I-NP', 'B-DNA')
('and', 'and', 'CC', 'O', 'I-DNA')
('3’untranslated', '3’untranslate', 'VBN', 'B-NP', 'I-DNA')
('regions', 'region', 'NNS', 'I-NP', 'I-DNA')
('(up', '(up', 'VBP', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('approximately', 'approximately', 'RB', 'B-NP', 'O')
('2', '2', 'CD', 'I-NP', 'B-DNA')
('kb', 'kb', 'NN', 'I-NP', 'I-DNA')
('upstream', 'upstream', 'RB', 'B-ADVP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('start', 'start', 'NN', 'I-NP', 'B-DNA')
('codon', 'codon', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('0.5', '0.5', 'CD', 'B-NP', 'O')
('kb', 'kb', 'NN', 'I-NP', 'O')
('downstream', 'downstream', 'RB', 'B-ADVP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('stop', 'stop', 'NN', 'I-NP', 'O')
('codon)', 'codon)', 'NN', 'I-NP', 'O')
('as', 'as', 'RB', 'B-CONJP', 'O')
('well', 'well', 'RB', 'I-CONJP', 'O')
('as', 'as', 'IN', 'I-CONJP', 'O')
('exonintron', 'exonintron', 'NN', 'B-NP', 'B-DNA')
('boundary', 'boundary', 'JJ', 'I-NP', 'I-DNA')
('regions', 'region', 'NNS', 'I-NP', 'I-DNA')
('using', 'use', 'VBG', 'B-VP', 'O')
('genomic', 'genomic', 'JJ', 'B-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('samples', 'sample', 'NNS', 'I-NP', 'O')
('collected', 'collect', 'VBN', 'B-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('24', '24', 'CD', 'B-NP', 'O')
('unrelated', 'unrelated', 'JJ', 'I-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'O')
('subjects.', 'subjects.', 'NNS', 'I-NP', 'O')
The ABI PRISM 3730 DNA analyzer (Applied BiosystemsTM) was used for sequencing and the primer sequences were designed based on GenBank sequences (NG_023252.1 for IL4 and NG_   012086 for IL4RA).
('The', 'The', 'DT', 'B-NP', 'O')
('ABI', 'ABI', 'NNP', 'I-NP', 'O')
('PRISM', 'PRISM', 'NNP', 'I-NP', 'O')
('3730', '3730', 'CD', 'I-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('analyzer', 'analyzer', 'NN', 'I-NP', 'O')
('(Applied', '(Applie', 'VBD', 'B-VP', 'O')
('BiosystemsTM)', 'BiosystemsTM)', 'NN', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('sequencing', 'sequencing', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('primer', 'primer', 'NN', 'I-NP', 'B-DNA')
('sequences', 'sequence', 'NNS', 'I-NP', 'I-DNA')
('were', 'be', 'VBD', 'B-VP', 'O')
('designed', 'design', 'VBN', 'I-VP', 'O')
('based', 'base', 'VBN', 'B-PP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('GenBank', 'GenBank', 'NNP', 'B-NP', 'O')
('sequences', 'sequence', 'NNS', 'I-NP', 'O')
('(NG_023252.1', '(NG_023252.1', 'NN', 'I-NP', 'B-protein')
('for', 'for', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('NG_', 'NG_', 'NN', 'B-NP', 'B-protein')
('012086', '012086', 'CD', 'I-NP', 'I-protein')
('for', 'for', 'IN', 'B-PP', 'O')
('IL4RA).', 'IL4RA).', 'NN', 'B-NP', 'B-protein')
SNPs with a minor allele frequency≥0.02 and a pair-wise r2 coefficient≥0.8 were selected for further genotyping.
('SNPs', 'SNP', 'NNS', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('minor', 'minor', 'JJ', 'I-NP', 'O')
('allele', 'allele', 'NN', 'I-NP', 'O')
('frequency≥0.02', 'frequency≥0.02', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('pair-wise', 'pair-wise', 'JJ', 'I-NP', 'O')
('r2', 'r2', 'NN', 'I-NP', 'O')
('coefficient≥0.8', 'coefficient≥0.8', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('selected', 'select', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('further', 'further', 'JJ', 'B-NP', 'O')
('genotyping.', 'genotyping.', 'NN', 'I-NP', 'O')
The VeraCode GoldenGate (Illumina, Inc. ) or TaqMan® (Life technologies) genotyping assay was employed using genomic DNA samples extracted from blood of study subjects.
('The', 'The', 'DT', 'B-NP', 'O')
('VeraCode', 'VeraCode', 'NNP', 'I-NP', 'O')
('GoldenGate', 'GoldenGate', 'NNP', 'I-NP', 'O')
('(Illumina,', '(Illumina,', 'NNP', 'I-NP', 'O')
('Inc.', 'Inc.', 'NNP', 'I-NP', 'O')
(')', ')', ')', 'O', 'O')
('or', 'or', 'CC', 'O', 'O')
('TaqMan®', 'TaqMan®', 'NN', 'B-NP', 'O')
('(Life', '(Life', 'NN', 'I-NP', 'O')
('technologies)', 'technologies)', 'NN', 'I-NP', 'O')
('genotyping', 'genotyping', 'NN', 'I-NP', 'O')
('assay', 'assay', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('employed', 'employ', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('genomic', 'genomic', 'JJ', 'B-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('samples', 'sample', 'NNS', 'I-NP', 'O')
('extracted', 'extract', 'VBN', 'B-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('blood', 'blood', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('study', 'study', 'NN', 'B-NP', 'O')
('subjects.', 'subjects.', 'NNS', 'I-NP', 'O')
Genotypes with concordance rates≥99% and call rates≥98% were only included for association analyses.
('Genotypes', 'Genotype', 'NNS', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('concordance', 'concordance', 'NN', 'B-NP', 'O')
('rates≥99%', 'rates≥99%', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('call', 'call', 'NN', 'B-NP', 'B-protein')
('rates≥98%', 'rates≥98%', 'NN', 'I-NP', 'I-protein')
('were', 'be', 'VBD', 'B-VP', 'O')
('only', 'only', 'RB', 'I-VP', 'O')
('included', 'include', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('association', 'association', 'NN', 'B-NP', 'O')
('analyses.', 'analyses.', 'NNS', 'I-NP', 'O')
Deviation from Hardy-Weinberg equilibrium (HWE) was tested using the χ2 test.
('Deviation', 'Deviation', 'NN', 'B-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('Hardy-Weinberg', 'Hardy-Weinberg', 'JJ', 'B-NP', 'O')
('equilibrium', 'equilibrium', 'NN', 'I-NP', 'O')
('(HWE)', '(HWE)', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('tested', 'test', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('χ2', 'χ2', 'NN', 'I-NP', 'O')
('test.', 'test.', 'NN', 'I-NP', 'O')
We examined linkage disequilibrium (LD) between all pairs of biallelic loci using Lewontin’s D’ (|D’|) and r2 coefficients, widely used measures for LD analysis.
('We', 'We', 'PRP', 'B-NP', 'O')
('examined', 'examine', 'VBD', 'B-VP', 'O')
('linkage', 'linkage', 'NN', 'B-NP', 'O')
('disequilibrium', 'disequilibrium', 'NN', 'I-NP', 'O')
('(LD)', '(LD)', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('all', 'all', 'DT', 'B-NP', 'O')
('pairs', 'pair', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('biallelic', 'biallelic', 'JJ', 'B-NP', 'O')
('loci', 'locus', 'NNS', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('Lewontin’s', 'Lewontin’', 'NNS', 'B-NP', 'O')
('D’', 'D’', 'NN', 'I-NP', 'O')
('(|D’|)', '(|D’|)', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('r2', 'r2', 'NN', 'I-NP', 'O')
('coefficients,', 'coefficients,', 'NN', 'I-NP', 'O')
('widely', 'widely', 'RB', 'B-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('measures', 'measure', 'NNS', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('LD', 'LD', 'NN', 'B-NP', 'O')
('analysis.', 'analysis.', 'NNS', 'I-NP', 'O')
Haplotypes of each individual were inferred using HaploView (Barrett et al., 2005).
('Haplotypes', 'Haplotype', 'NNS', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('each', 'each', 'DT', 'B-NP', 'O')
('individual', 'individual', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('inferred', 'infer', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('HaploView', 'HaploView', 'NNP', 'B-NP', 'O')
('(Barrett', '(Barrett', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
Logistic regression analyses were conducted to determine the odds ratio (OR) (95% confidence interval (CI)) for the risk of T2DM, controlling for the covariates of age, sex, and BMI.
('Logistic', 'Logistic', 'JJ', 'B-NP', 'O')
('regression', 'regression', 'NN', 'I-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('conducted', 'conduct', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('determine', 'determine', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('odds', 'odd', 'NNS', 'I-NP', 'O')
('ratio', 'ratio', 'NN', 'I-NP', 'O')
('(OR)', '(OR)', 'NN', 'I-NP', 'O')
('(95%', '(95%', 'NN', 'I-NP', 'O')
('confidence', 'confidence', 'NN', 'I-NP', 'O')
('interval', 'interval', 'NN', 'I-NP', 'O')
('(CI))', '(CI))', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('T2DM,', 'T2DM,', 'NN', 'B-NP', 'B-protein')
('controlling', 'control', 'VBG', 'B-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('covariates', 'covariate', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('age,', 'age,', 'NN', 'B-NP', 'O')
('sex,', 'sex,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('BMI.', 'BMI.', 'NN', 'B-NP', 'O')
Multivariate linear regression analyses were performed to test for associations among T2DM-related intermediate phenotypes such as BMI, serum glucose and insulin level among the unaffected group, controlling for age and sex.
('Multivariate', 'Multivariate', 'JJ', 'B-NP', 'O')
('linear', 'linear', 'JJ', 'I-NP', 'O')
('regression', 'regression', 'NN', 'I-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('performed', 'perform', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('test', 'test', 'VB', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('associations', 'association', 'NNS', 'B-NP', 'O')
('among', 'among', 'IN', 'B-PP', 'O')
('T2DM-related', 'T2DM-related', 'JJ', 'B-NP', 'O')
('intermediate', 'intermediate', 'JJ', 'I-NP', 'O')
('phenotypes', 'phenotype', 'NNS', 'I-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('BMI,', 'BMI,', 'NN', 'B-NP', 'O')
('serum', 'serum', 'NN', 'I-NP', 'O')
('glucose', 'glucose', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'B-protein')
('level', 'level', 'NN', 'I-NP', 'O')
('among', 'among', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('unaffected', 'unaffected', 'JJ', 'I-NP', 'O')
('group,', 'group,', 'NN', 'I-NP', 'O')
('controlling', 'control', 'VBG', 'B-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('age', 'age', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('sex.', 'sex.', 'NN', 'I-NP', 'O')
Statistical analyses were performed using SAS (SAS institute).
('Statistical', 'Statistical', 'JJ', 'B-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('performed', 'perform', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('SAS', 'SAS', 'NN', 'B-NP', 'O')
('(SAS', '(SAS', 'NN', 'I-NP', 'O')
('institute).', 'institute).', 'NN', 'I-NP', 'O')
The inverse variance meta-analysis method was employed for combined analysis of the two-stage association study, assuming fixed effects.
('The', 'The', 'DT', 'B-NP', 'O')
('inverse', 'inverse', 'JJ', 'I-NP', 'O')
('variance', 'variance', 'NN', 'I-NP', 'O')
('meta-analysis', 'meta-analysis', 'NN', 'I-NP', 'O')
('method', 'method', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('employed', 'employ', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('combined', 'combine', 'VBN', 'B-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('two-stage', 'two-stage', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('study,', 'study,', 'NN', 'I-NP', 'O')
('assuming', 'assume', 'VBG', 'B-VP', 'O')
('fixed', 'fix', 'VBN', 'B-NP', 'O')
('effects.', 'effects.', 'NNS', 'I-NP', 'O')
The R program (version 2.7.1) was used for the analysis.
('The', 'The', 'DT', 'B-NP', 'O')
('R', 'R', 'NN', 'I-NP', 'B-protein')
('program', 'program', 'NN', 'I-NP', 'I-protein')
('(version', '(version', 'NN', 'I-NP', 'I-protein')
('2.7.1)', '2.7.1)', 'CD', 'I-NP', 'I-protein')
('was', 'be', 'VBD', 'B-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('analysis.', 'analysis.', 'NN', 'I-NP', 'O')
Heterogeneity was verified using Cochran’s Q test.
('Heterogeneity', 'Heterogeneity', 'NN', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('verified', 'verify', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('Cochran’s', 'Cochran’', 'NNS', 'B-NP', 'O')
('Q', 'Q', 'NN', 'I-NP', 'O')
('test.', 'test.', 'NN', 'I-NP', 'O')
Gene-gene interaction between the IL4 and IL4RA SNPs was analyzed using the logistic regression method.
('Gene-gene', 'Gene-gene', 'JJ', 'B-NP', 'O')
('interaction', 'interaction', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4RA', 'IL4RA', 'NN', 'I-NP', 'B-protein')
('SNPs', 'SNP', 'NNS', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('analyzed', 'analyze', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('logistic', 'logistic', 'JJ', 'I-NP', 'O')
('regression', 'regression', 'NN', 'I-NP', 'O')
('method.', 'method.', 'NN', 'I-NP', 'O')
A combination of the homozygous genotype of the major allele of both genes (TT for rs2243250T＞C and CC for rs3024610C＞T) was used as a reference of epistasis.
('A', 'A', 'DT', 'B-NP', 'O')
('combination', 'combination', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('homozygous', 'homozygous', 'JJ', 'I-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('major', 'major', 'JJ', 'I-NP', 'B-DNA')
('allele', 'allele', 'NN', 'I-NP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('both', 'both', 'DT', 'B-NP', 'O')
('genes', 'gene', 'NNS', 'I-NP', 'O')
('(TT', '(TT', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('rs2243250T＞C', 'rs2243250T＞C', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('CC', 'CC', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('rs3024610C＞T)', 'rs3024610C＞T)', 'NN', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('reference', 'reference', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('epistasis.', 'epistasis.', 'NN', 'B-NP', 'O')
Correction for multiple testing was conducted following the false discovery rate (FDR)-controlling methods of Benjamini and Hochberg.
('Correction', 'Correction', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('multiple', 'multiple', 'JJ', 'B-NP', 'O')
('testing', 'testing', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('conducted', 'conduct', 'VBN', 'I-VP', 'O')
('following', 'follow', 'VBG', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('false', 'false', 'JJ', 'I-NP', 'O')
('discovery', 'discovery', 'NN', 'I-NP', 'O')
('rate', 'rate', 'NN', 'I-NP', 'O')
('(FDR)-controlling', '(FDR)-controlling', 'JJ', 'I-NP', 'O')
('methods', 'method', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Benjamini', 'Benjamini', 'NNP', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('Hochberg.', 'Hochberg.', 'NNP', 'I-NP', 'O')
The transcription factor binding of the SNPcontaining region was analyzed using FASTSNP (http://fastsnp.
('The', 'The', 'DT', 'B-NP', 'O')
('transcription', 'transcription', 'NN', 'I-NP', 'B-protein')
('factor', 'factor', 'NN', 'I-NP', 'I-protein')
('binding', 'binding', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNPcontaining', 'SNPcontaine', 'VBG', 'I-NP', 'B-DNA')
('region', 'region', 'NN', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('analyzed', 'analyze', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('FASTSNP', 'FASTSNP', 'NN', 'B-NP', 'B-protein')
('(http://fastsnp.', '(http://fastsnp.', '.', 'O', 'O')
ibms.
('ibms.', 'ibms.', 'LS', 'B-LST', 'O')
sinica.
('sinica.', 'sinica.', 'LS', 'B-LST', 'O')
edu.
('edu.', 'edu.', 'LS', 'B-LST', 'O')
tw/pages/input_CandidateGeneSearch.
('tw/pages/input_CandidateGeneSearch.', 'tw/pages/input_CandidateGeneSearch.', 'NN', 'B-NP', 'O')
jsp).
('jsp).', 'jsp).', 'LS', 'B-LST', 'O')
The genomic region (－433 to +353 with respect to the transcription initiation site of NM_000589 as +1) of IL4 was amplified using standard PCR methods.
('The', 'The', 'DT', 'B-NP', 'O')
('genomic', 'genomic', 'JJ', 'I-NP', 'O')
('region', 'region', 'NN', 'I-NP', 'O')
('(－433', '(－433', 'CD', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('+353', '+353', 'CD', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('respect', 'respect', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('transcription', 'transcription', 'NN', 'I-NP', 'B-DNA')
('initiation', 'initiation', 'NN', 'I-NP', 'I-DNA')
('site', 'site', 'NN', 'I-NP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('NM_000589', 'NM_000589', 'NN', 'B-NP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('+1)', '+1)', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('was', 'be', 'VBD', 'B-VP', 'O')
('amplified', 'amplify', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('standard', 'standard', 'JJ', 'B-NP', 'O')
('PCR', 'PCR', 'NN', 'I-NP', 'O')
('methods.', 'methods.', 'NN', 'I-NP', 'O')
DNA samples extracted from rs2243250T or rs2243250C carriers were used as a template for PCR.
('DNA', 'DNA', 'NN', 'B-NP', 'O')
('samples', 'sample', 'NNS', 'I-NP', 'O')
('extracted', 'extract', 'VBN', 'B-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('rs2243250T', 'rs2243250T', 'NN', 'B-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('rs2243250C', 'rs2243250C', 'NN', 'I-NP', 'O')
('carriers', 'carrier', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('template', 'template', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('PCR.', 'PCR.', 'NN', 'B-NP', 'O')
Sequences of the oligonucleotide primers used for amplification are as follows: 5' to 3' primer, CCTGATCACAACATTGCATTTCAGC; 3' to 5' primer, CAGTGACAATGTGAGGCAATTAGTTTATC.
('Sequences', 'Sequence', 'NNS', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('oligonucleotide', 'oligonucleotide', 'NN', 'I-NP', 'O')
('primers', 'primer', 'NNS', 'I-NP', 'O')
('used', 'use', 'VBN', 'B-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('amplification', 'amplification', 'NN', 'B-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('follows:', 'follows:', 'NN', 'B-NP', 'O')
("5'", "5'", 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
("3'", "3'", 'JJ', 'B-NP', 'O')
('primer,', 'primer,', 'NN', 'I-NP', 'O')
('CCTGATCACAACATTGCATTTCAGC;', 'CCTGATCACAACATTGCATTTCAGC;', 'NN', 'I-NP', 'O')
("3'", "3'", 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
("5'", "5'", 'JJ', 'B-NP', 'B-DNA')
('primer,', 'primer,', 'NN', 'I-NP', 'I-DNA')
('CAGTGACAATGTGAGGCAATTAGTTTATC.', 'CAGTGACAATGTGAGGCAATTAGTTTATC.', 'NNP', 'B-NP', 'O')
Each PCR product was thoroughly sequenced prior to insertion into the upstream region of the bla (M) reporter gene, coding for βlactamase (GeneBLAzerTM, Invitrogen), to ensure the SNP sequence and the proper sequence identity of the constructs except for the SNP of interest.
('Each', 'Each', 'DT', 'B-NP', 'O')
('PCR', 'PCR', 'NN', 'I-NP', 'B-DNA')
('product', 'product', 'NN', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('thoroughly', 'thoroughly', 'RB', 'I-VP', 'O')
('sequenced', 'sequence', 'VBN', 'I-VP', 'O')
('prior', 'prior', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('insertion', 'insertion', 'NN', 'B-NP', 'O')
('into', 'into', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('upstream', 'upstream', 'JJ', 'I-NP', 'B-DNA')
('region', 'region', 'NN', 'I-NP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('bla', 'bla', 'NN', 'I-NP', 'O')
('(M)', '(M)', 'NN', 'I-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'O')
('gene,', 'gene,', 'NN', 'I-NP', 'O')
('coding', 'cod', 'VBG', 'B-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('βlactamase', 'βlactamase', 'NN', 'B-NP', 'O')
('(GeneBLAzerTM,', '(GeneBLAzerTM,', 'NNP', 'I-NP', 'O')
('Invitrogen),', 'Invitrogen),', 'NNP', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('ensure', 'ensure', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNP', 'SNP', 'NN', 'I-NP', 'B-DNA')
('sequence', 'sequence', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('proper', 'proper', 'JJ', 'I-NP', 'O')
('sequence', 'sequence', 'NN', 'I-NP', 'O')
('identity', 'identity', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('constructs', 'construct', 'NNS', 'I-NP', 'O')
('except', 'except', 'IN', 'B-PP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNP', 'SNP', 'NN', 'I-NP', 'B-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('interest.', 'interest.', 'NN', 'B-NP', 'O')
Plasmid DNA of the reporter constructs was prepared for transfection using an endotoxinfree DNA preparation kit (Qiagen).
('Plasmid', 'Plasmid', 'NN', 'B-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'B-DNA')
('constructs', 'construct', 'NNS', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('prepared', 'prepare', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('transfection', 'transfection', 'NN', 'B-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('endotoxinfree', 'endotoxinfree', 'JJ', 'I-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('preparation', 'preparation', 'NN', 'I-NP', 'O')
('kit', 'kit', 'NN', 'I-NP', 'O')
('(Qiagen).', '(Qiagen).', 'NN', 'I-NP', 'O')
For transfection, cells of the human hepatocellular carcinoma cell line SNU398 or the human adipocyte cell line SW872 (3 ×104 per well) were plated in a blackwalled 96well tissueculture plate with a clear bottom (Costar).
('For', 'For', 'IN', 'B-PP', 'O')
('transfection,', 'transfection,', 'NN', 'B-NP', 'O')
('cells', 'cell', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('human', 'human', 'JJ', 'I-NP', 'B-cell_line')
('hepatocellular', 'hepatocellular', 'JJ', 'I-NP', 'I-cell_line')
('carcinoma', 'carcinoma', 'NN', 'I-NP', 'I-cell_line')
('cell', 'cell', 'NN', 'I-NP', 'I-cell_line')
('line', 'line', 'NN', 'I-NP', 'I-cell_line')
('SNU398', 'SNU398', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('human', 'human', 'JJ', 'I-NP', 'B-cell_line')
('adipocyte', 'adipocyte', 'NN', 'I-NP', 'I-cell_line')
('cell', 'cell', 'NN', 'I-NP', 'I-cell_line')
('line', 'line', 'NN', 'I-NP', 'I-cell_line')
('SW872', 'SW872', 'NN', 'I-NP', 'O')
('(3', '(3', 'NN', 'I-NP', 'O')
('×104', '×104', 'NN', 'I-NP', 'O')
('per', 'per', 'IN', 'B-PP', 'O')
('well)', 'well)', 'NN', 'B-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('plated', 'plat', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('blackwalled', 'blackwalled', 'JJ', 'I-NP', 'O')
('96well', '96well', 'CD', 'I-NP', 'O')
('tissueculture', 'tissueculture', 'NN', 'I-NP', 'O')
('plate', 'plate', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('clear', 'clear', 'JJ', 'I-NP', 'O')
('bottom', 'bottom', 'NN', 'I-NP', 'O')
('(Costar).', '(Costar).', 'NNP', 'B-NP', 'O')
After a 24 hrincubation period, the cells were transfected with 400 ng of purified reporter plasmid DNA using Lipofectamine 2000 transfection reagent (Invitrogen).
('After', 'After', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('24', '24', 'CD', 'I-NP', 'O')
('hrincubation', 'hrincubation', 'NN', 'I-NP', 'O')
('period,', 'period,', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cells', 'cell', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('transfected', 'transfecte', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('400', '400', 'CD', 'B-NP', 'O')
('ng', 'ng', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('purified', 'purify', 'VBN', 'B-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'O')
('plasmid', 'plasmid', 'NN', 'I-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('Lipofectamine', 'Lipofectamine', 'NN', 'B-NP', 'O')
('2000', '2000', 'CD', 'I-NP', 'O')
('transfection', 'transfection', 'NN', 'I-NP', 'O')
('reagent', 'reagent', 'NN', 'I-NP', 'O')
('(Invitrogen).', '(Invitrogen).', 'NN', 'I-NP', 'O')
The reporter βlactamase activity was quantitatively measured from the transiently transfected cells after 48 hrs of incubation at 37oC, 5% CO2, following the manufacturer's instructions (Invitrogen, GeneBLAzerTM in vivo detection kit).
('The', 'The', 'DT', 'B-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'O')
('βlactamase', 'βlactamase', 'NN', 'I-NP', 'O')
('activity', 'activity', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('quantitatively', 'quantitatively', 'RB', 'I-VP', 'O')
('measured', 'measure', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('transiently', 'transiently', 'RB', 'I-NP', 'B-cell_line')
('transfected', 'transfecte', 'VBN', 'I-NP', 'I-cell_line')
('cells', 'cell', 'NNS', 'I-NP', 'I-cell_line')
('after', 'after', 'IN', 'B-PP', 'O')
('48', '48', 'CD', 'B-NP', 'O')
('hrs', 'hr', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('incubation', 'incubation', 'NN', 'B-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('37oC,', '37oC,', 'NN', 'B-NP', 'O')
('5%', '5%', 'CD', 'I-NP', 'O')
('CO2,', 'CO2,', 'NN', 'I-NP', 'O')
('following', 'follow', 'VBG', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
("manufacturer's", "manufacturer'", 'NNS', 'I-NP', 'O')
('instructions', 'instruction', 'NNS', 'I-NP', 'O')
('(Invitrogen,', '(Invitrogen,', 'NN', 'I-NP', 'O')
('GeneBLAzerTM', 'GeneBLAzerTM', 'NN', 'I-NP', 'O')
('in', 'in', 'FW', 'B-NP', 'O')
('vivo', 'vivo', 'FW', 'I-NP', 'O')
('detection', 'detection', 'NN', 'I-NP', 'O')
('kit).', 'kit).', 'NN', 'I-NP', 'O')
The normalized activity was presented as a relative ratio with respect to that of cells transfected without DNA.
('The', 'The', 'DT', 'B-NP', 'O')
('normalized', 'normalized', 'JJ', 'I-NP', 'O')
('activity', 'activity', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('presented', 'present', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('relative', 'relative', 'JJ', 'I-NP', 'O')
('ratio', 'ratio', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('respect', 'respect', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('that', 'that', 'DT', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('cells', 'cell', 'NNS', 'B-NP', 'O')
('transfected', 'transfecte', 'VBN', 'B-VP', 'O')
('without', 'without', 'IN', 'B-PP', 'O')
('DNA.', 'DNA.', 'NN', 'B-NP', 'O')
To explore the possibility that IL4 and IL4RA are associated with the risk of T2DM, we first attempted to identify SNPs in the Korean population by sequencing the gene loci including 5’ and 3’flanking regions.
('To', 'To', 'TO', 'B-VP', 'O')
('explore', 'explore', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('possibility', 'possibility', 'NN', 'I-NP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4RA', 'IL4RA', 'NN', 'I-NP', 'B-protein')
('are', 'be', 'VBP', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('T2DM,', 'T2DM,', 'NN', 'B-NP', 'B-protein')
('we', 'we', 'PRP', 'B-NP', 'O')
('first', 'first', 'RB', 'B-ADVP', 'O')
('attempted', 'attempt', 'VBD', 'B-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('identify', 'identify', 'VB', 'I-VP', 'O')
('SNPs', 'SNP', 'NNS', 'B-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'B-cell_line')
('population', 'population', 'NN', 'I-NP', 'I-cell_line')
('by', 'by', 'IN', 'B-PP', 'O')
('sequencing', 'sequence', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('loci', 'locus', 'NNS', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('5’', '5’', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('3’flanking', '3’flanke', 'VBG', 'B-VP', 'O')
('regions.', 'regions.', 'NNS', 'B-NP', 'O')
Among the identified SNPs (Supplementary Fig.
('Among', 'Among', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('identified', 'identify', 'VBN', 'I-NP', 'O')
('SNPs', 'SNPs', 'NNP', 'I-NP', 'O')
('(Supplementary', '(Supplementary', 'NNP', 'I-NP', 'O')
('Fig.', 'Fig.', 'NNP', 'I-NP', 'O')
and Supplementary Tables 11 and 12), we selected two and eight SNPs from the IL4 and IL4RA loci, respectively, considering LD and allele frequencies for largescale genotyping.
('and', 'and', 'CC', 'O', 'O')
('Supplementary', 'Supplementary', 'JJ', 'B-NP', 'O')
('Tables', 'Table', 'NNS', 'I-NP', 'O')
('11', '11', 'CD', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('12),', '12),', 'CD', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('selected', 'select', 'VBD', 'B-VP', 'O')
('two', 'two', 'CD', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('eight', 'eight', 'CD', 'I-NP', 'O')
('SNPs', 'SNP', 'NNS', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4RA', 'IL4RA', 'NN', 'I-NP', 'B-protein')
('loci,', 'loci,', 'NN', 'I-NP', 'O')
('respectively,', 'respectively,', 'NN', 'I-NP', 'O')
('considering', 'consider', 'VBG', 'B-VP', 'O')
('LD', 'LD', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('allele', 'allele', 'NN', 'I-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('largescale', 'largescale', 'JJ', 'B-NP', 'O')
('genotyping.', 'genotyping.', 'NN', 'I-NP', 'O')
We genotyped 474 unrelated T2DM cases and 470 nondiabetic control subjects to test for association of the polymorphisms with host susceptibility to the disease.
('We', 'We', 'PRP', 'B-NP', 'O')
('genotyped', 'genotype', 'VBD', 'B-VP', 'O')
('474', '474', 'CD', 'B-NP', 'O')
('unrelated', 'unrelated', 'JJ', 'I-NP', 'O')
('T2DM', 'T2DM', 'NN', 'I-NP', 'O')
('cases', 'case', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('470', '470', 'CD', 'B-NP', 'O')
('nondiabetic', 'nondiabetic', 'JJ', 'I-NP', 'O')
('control', 'control', 'NN', 'I-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('test', 'test', 'VB', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('association', 'association', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('host', 'host', 'NN', 'B-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('disease.', 'disease.', 'NN', 'I-NP', 'O')
The subjects were recruited from Ansan and Ansung communitybased cohorts as part of KoGES (Table 1).
('The', 'The', 'DT', 'B-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('recruited', 'recruit', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('Ansan', 'Ansan', 'NNP', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('Ansung', 'Ansung', 'NNP', 'I-NP', 'O')
('communitybased', 'communitybased', 'JJ', 'I-NP', 'O')
('cohorts', 'cohort', 'NNS', 'I-NP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('part', 'part', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('KoGES', 'KoGES', 'NNP', 'B-NP', 'O')
('(Table', '(Table', 'NNP', 'I-NP', 'O')
('1).', '1).', '.', 'O', 'O')
In the casecontrol study using logistic regression analysis with adjustment for age, sex, and BMI, we found no differences in the distribution of genotype frequencies between the control and T2DM cases for any of the SNPs tested, with exception of a promoter variant on the IL4 locus, rs2243250T＞C.
('In', 'In', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('casecontrol', 'casecontrol', 'NN', 'I-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('logistic', 'logistic', 'JJ', 'B-NP', 'O')
('regression', 'regression', 'NN', 'I-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('adjustment', 'adjustment', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('age,', 'age,', 'NN', 'B-NP', 'O')
('sex,', 'sex,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('BMI,', 'BMI,', 'NN', 'I-NP', 'B-protein')
('we', 'we', 'PRP', 'B-NP', 'O')
('found', 'find', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('differences', 'difference', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('distribution', 'distribution', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('genotype', 'genotype', 'NN', 'B-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('control', 'control', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('T2DM', 'T2DM', 'NN', 'I-NP', 'O')
('cases', 'case', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('any', 'any', 'DT', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNPs', 'SNP', 'NNS', 'I-NP', 'O')
('tested,', 'tested,', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('exception', 'exception', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('promoter', 'promoter', 'NN', 'I-NP', 'O')
('variant', 'variant', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('locus,', 'locus,', 'NN', 'I-NP', 'O')
('rs2243250T＞C.', 'rs2243250T＞C.', 'NN', 'I-NP', 'O')
The analysis revealed that the minor allele C had a protective effect on T2DM risk compared to that of the major allele T (protective allele OR=0.70; 95% CI, 0.55∼0.89; p=0.004 (FDRP ＜ 0.05) in an additive model, Table 2).
('The', 'The', 'DT', 'B-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('revealed', 'reveal', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('minor', 'minor', 'JJ', 'I-NP', 'O')
('allele', 'allele', 'NN', 'I-NP', 'O')
('C', 'C', 'NN', 'I-NP', 'O')
('had', 'have', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('protective', 'protective', 'JJ', 'I-NP', 'O')
('effect', 'effect', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('compared', 'compare', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('that', 'that', 'DT', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('major', 'major', 'JJ', 'I-NP', 'O')
('allele', 'allele', 'NN', 'I-NP', 'O')
('T', 'T', 'NN', 'I-NP', 'O')
('(protective', '(protective', 'JJ', 'I-NP', 'O')
('allele', 'allele', 'NN', 'I-NP', 'O')
('OR=0.70;', 'OR=0.70;', 'NN', 'I-NP', 'O')
('95%', '95%', 'CD', 'B-NP', 'O')
('CI,', 'CI,', 'NN', 'I-NP', 'O')
('0.55∼0.89;', '0.55∼0.89;', 'CD', 'B-NP', 'O')
('p=0.004', 'p=0.004', 'NN', 'I-NP', 'O')
('(FDRP', '(FDRP', 'NN', 'I-NP', 'O')
('＜', '＜', 'IN', 'B-PP', 'O')
('0.05)', '0.05)', 'CD', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('additive', 'additive', 'JJ', 'I-NP', 'O')
('model,', 'model,', 'NN', 'I-NP', 'O')
('Table', 'Table', 'JJ', 'I-NP', 'O')
('2).', '2).', 'CD', 'I-NP', 'O')
To confirm these results, we conducted a second   　　　stage case-control association analysis by genotyping samples from another community-based cohort, Health 2 of KoGES.
('To', 'To', 'TO', 'B-VP', 'O')
('confirm', 'confirm', 'VB', 'I-VP', 'O')
('these', 'these', 'DT', 'B-NP', 'O')
('results,', 'results,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('conducted', 'conduct', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('second', 'second', 'JJ', 'I-NP', 'O')
('\u3000\u3000\u3000stage', '\u3000\u3000\u3000stage', 'NN', 'I-NP', 'O')
('case-control', 'case-control', 'NN', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('genotyping', 'genotyping', 'NN', 'B-NP', 'O')
('samples', 'sample', 'NNS', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('another', 'another', 'DT', 'B-NP', 'O')
('community-based', 'community-based', 'JJ', 'I-NP', 'O')
('cohort,', 'cohort,', 'NN', 'I-NP', 'O')
('Health', 'Health', 'NNP', 'B-NP', 'O')
('2', '2', 'CD', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('KoGES.', 'KoGES.', 'NNP', 'B-NP', 'O')
The genotyping of 1,216 cases and 1,352 controls generated additional evidence supporting the association of rs2243250T＞C with T2DM (OR=0.80; 95% CI, 0.67∼0.94; p=0.007 (FDR-P＜0.05)).
('The', 'The', 'DT', 'B-NP', 'O')
('genotyping', 'genotyping', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('1,216', '1,216', 'CD', 'B-NP', 'O')
('cases', 'case', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('1,352', '1,352', 'CD', 'B-NP', 'O')
('controls', 'control', 'NNS', 'I-NP', 'O')
('generated', 'generate', 'VBD', 'B-VP', 'O')
('additional', 'additional', 'JJ', 'B-NP', 'O')
('evidence', 'evidence', 'NN', 'I-NP', 'O')
('supporting', 'support', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('rs2243250T＞C', 'rs2243250T＞C', 'NN', 'B-NP', 'B-protein')
('with', 'with', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('(OR=0.80;', '(OR=0.80;', 'NN', 'I-NP', 'O')
('95%', '95%', 'CD', 'I-NP', 'O')
('CI,', 'CI,', 'NNP', 'I-NP', 'O')
('0.67∼0.94;', '0.67∼0.94;', 'CD', 'I-NP', 'O')
('p=0.007', 'p=0.007', 'NN', 'I-NP', 'O')
('(FDR-P＜0.05)).', '(FDR-P＜0.05)).', 'NN', 'I-NP', 'O')
A meta analysis of the data of the two cohorts produced stronger combined evidence of association (OR=0.77; 95% CI, 0.67∼0.88; p=1.65×10-4 (FDR-P＜0.05); Table 2).
('A', 'A', 'DT', 'B-NP', 'O')
('meta', 'meta', 'JJ', 'I-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('data', 'datum', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('two', 'two', 'CD', 'I-NP', 'O')
('cohorts', 'cohort', 'NNS', 'I-NP', 'O')
('produced', 'produce', 'VBD', 'B-VP', 'O')
('stronger', 'strong', 'JJR', 'B-NP', 'O')
('combined', 'combine', 'VBN', 'I-NP', 'O')
('evidence', 'evidence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('association', 'association', 'NN', 'B-NP', 'O')
('(OR=0.77;', '(OR=0.77;', 'NN', 'I-NP', 'O')
('95%', '95%', 'CD', 'I-NP', 'O')
('CI,', 'CI,', 'NNP', 'I-NP', 'O')
('0.67∼0.88;', '0.67∼0.88;', 'CD', 'I-NP', 'O')
('p=1.65×10-4', 'p=1.65×10-4', 'NN', 'I-NP', 'O')
('(FDR-P＜0.05);', '(FDR-P＜0.05);', 'NN', 'I-NP', 'O')
('Table', 'Table', 'JJ', 'I-NP', 'O')
('2).', '2).', 'CD', 'I-NP', 'O')
Although our analyses of individual SNPs or haplotypes revealed no evidence of IL4RA association with T2DM, the linear regression analyses for T2DMrelated intermediate phenotypes such as BMI, WHR, plasma glucose and insulin level in the controls showed modest association signals of IL4RA polymorphisms with BMI and insulin level in either or both populations (Supplementary Table 2).
('Although', 'Although', 'IN', 'B-SBAR', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('individual', 'individual', 'JJ', 'B-NP', 'O')
('SNPs', 'SNP', 'NNS', 'I-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('haplotypes', 'haplotype', 'NNS', 'I-NP', 'O')
('revealed', 'reveal', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('evidence', 'evidence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4RA', 'IL4RA', 'NN', 'B-NP', 'B-protein')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('T2DM,', 'T2DM,', 'NN', 'B-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('linear', 'linear', 'JJ', 'I-NP', 'O')
('regression', 'regression', 'NN', 'I-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('T2DMrelated', 'T2DMrelated', 'JJ', 'B-NP', 'O')
('intermediate', 'intermediate', 'JJ', 'I-NP', 'O')
('phenotypes', 'phenotype', 'NNS', 'I-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('BMI,', 'BMI,', 'NNP', 'B-NP', 'O')
('WHR,', 'WHR,', 'NNP', 'I-NP', 'O')
('plasma', 'plasma', 'NN', 'I-NP', 'O')
('glucose', 'glucose', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'B-protein')
('level', 'level', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('controls', 'control', 'NNS', 'I-NP', 'O')
('showed', 'show', 'VBD', 'B-VP', 'O')
('modest', 'modest', 'JJ', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('signals', 'signal', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4RA', 'IL4RA', 'NN', 'B-NP', 'B-protein')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('BMI', 'BMI', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'B-protein')
('level', 'level', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('either', 'either', 'DT', 'B-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('both', 'both', 'DT', 'B-NP', 'O')
('populations', 'population', 'NNS', 'I-NP', 'O')
('(Supplementary', '(Supplementary', 'JJ', 'B-NP', 'O')
('Table', 'Table', 'JJ', 'I-NP', 'O')
('2).', '2).', 'NN', 'I-NP', 'O')
This result led us to examine the effect of IL4-IL4RA interaction on disease susceptibility.
('This', 'This', 'DT', 'B-NP', 'O')
('result', 'result', 'NN', 'I-NP', 'O')
('led', 'lead', 'VBD', 'B-VP', 'O')
('us', 'us', 'PRP', 'B-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('examine', 'examine', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('effect', 'effect', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4-IL4RA', 'IL4-IL4RA', 'NN', 'B-NP', 'O')
('interaction', 'interaction', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('disease', 'disease', 'NN', 'B-NP', 'O')
('susceptibility.', 'susceptibility.', 'NN', 'I-NP', 'O')
Logistic analysis for epistasis between rs2243250T＞C of IL4 and the tagging SNPs of IL4RA (Table 2) showed existence of an interaction between the IL4 SNPs and an intronic SNP, rs3024610C＞T (Table 3).
('Logistic', 'Logistic', 'JJ', 'B-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('epistasis', 'epistasis', 'NN', 'B-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('rs2243250T＞C', 'rs2243250T＞C', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('tagging', 'tag', 'VBG', 'I-NP', 'O')
('SNPs', 'SNP', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4RA', 'IL4RA', 'NN', 'B-NP', 'B-protein')
('(Table', '(Table', 'JJ', 'I-NP', 'O')
('2)', '2)', 'NN', 'I-NP', 'O')
('showed', 'show', 'VBD', 'B-VP', 'O')
('existence', 'existence', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('interaction', 'interaction', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('SNPs', 'SNP', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('intronic', 'intronic', 'JJ', 'I-NP', 'O')
('SNP,', 'SNP,', 'NN', 'I-NP', 'O')
('rs3024610C＞T', 'rs3024610C＞T', 'NN', 'I-NP', 'O')
('(Table', '(Table', 'JJ', 'B-ADJP', 'O')
('3).', '3).', 'CD', 'B-NP', 'O')
The heterozygous genotype for rs2243250T＞C (TC) and the homozygous genotype for rs3024610C＞T (CC) showed significant association with a protective effect in the first stage, compared to the TT×CC as a reference (OR= 0.40; 95% CI, 0.22∼0.73; p=0.003).
('The', 'The', 'DT', 'B-NP', 'O')
('heterozygous', 'heterozygous', 'JJ', 'I-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('rs2243250T＞C', 'rs2243250T＞C', 'NN', 'B-NP', 'B-protein')
('(TC)', '(TC)', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('homozygous', 'homozygous', 'JJ', 'I-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('rs3024610C＞T', 'rs3024610C＞T', 'NN', 'B-NP', 'O')
('(CC)', '(CC)', 'NN', 'I-NP', 'O')
('showed', 'show', 'VBD', 'B-VP', 'O')
('significant', 'significant', 'JJ', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('protective', 'protective', 'JJ', 'I-NP', 'O')
('effect', 'effect', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('first', 'first', 'JJ', 'I-NP', 'O')
('stage,', 'stage,', 'NN', 'I-NP', 'O')
('compared', 'compare', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('TT×CC', 'TT×CC', 'NN', 'I-NP', 'B-DNA')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('reference', 'reference', 'NN', 'I-NP', 'O')
('(OR=', '(OR=', 'NNP', 'B-NP', 'O')
('0.40;', '0.40;', 'CD', 'I-NP', 'O')
('95%', '95%', 'CD', 'I-NP', 'O')
('CI,', 'CI,', 'NNP', 'I-NP', 'O')
('0.22∼0.73;', '0.22∼0.73;', 'CD', 'I-NP', 'O')
('p=0.003).', 'p=0.003).', 'NN', 'I-NP', 'O')
In the second stage analysis, a combination of the heterozygous genotypes for both SNPs (TC×CT) displayed a moderate association in the same direction (OR=0.72; 95% CI, 0.5333∼0.98; p=0.034).
('In', 'In', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('second', 'second', 'JJ', 'I-NP', 'O')
('stage', 'stage', 'NN', 'I-NP', 'O')
('analysis,', 'analysis,', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('combination', 'combination', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('heterozygous', 'heterozygous', 'JJ', 'I-NP', 'O')
('genotypes', 'genotype', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('both', 'both', 'DT', 'B-NP', 'O')
('SNPs', 'SNP', 'NNS', 'I-NP', 'O')
('(TC×CT)', '(TC×CT)', 'NN', 'I-NP', 'B-protein')
('displayed', 'display', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('moderate', 'moderate', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('same', 'same', 'JJ', 'I-NP', 'O')
('direction', 'direction', 'NN', 'I-NP', 'O')
('(OR=0.72;', '(OR=0.72;', 'NN', 'I-NP', 'O')
('95%', '95%', 'CD', 'I-NP', 'O')
('CI,', 'CI,', 'NNP', 'I-NP', 'O')
('0.5333∼0.98;', '0.5333∼0.98;', 'CD', 'I-NP', 'O')
('p=0.034).', 'p=0.034).', 'NN', 'I-NP', 'O')
Although the same combination of genotypes was not replicated, these results suggest that interaction of IL4 and IL4RA has a cumulative effect on T2DM risk, compared to the effects from the individual SNPs.
('Although', 'Although', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('same', 'same', 'JJ', 'I-NP', 'O')
('combination', 'combination', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('genotypes', 'genotype', 'NNS', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('replicated,', 'replicated,', 'VB', 'I-VP', 'O')
('these', 'these', 'DT', 'B-NP', 'O')
('results', 'result', 'NNS', 'I-NP', 'O')
('suggest', 'suggest', 'VBP', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('interaction', 'interaction', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4RA', 'IL4RA', 'NN', 'I-NP', 'B-protein')
('has', 'have', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('cumulative', 'cumulative', 'JJ', 'I-NP', 'O')
('effect', 'effect', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('risk,', 'risk,', 'NN', 'I-NP', 'O')
('compared', 'compare', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('effects', 'effect', 'NNS', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('individual', 'individual', 'JJ', 'I-NP', 'O')
('SNPs.', 'SNPs.', 'NN', 'I-NP', 'O')
The strong association of rs2243250T＞C with T2DM   and its close proximity to the IL4 transcription initiation site (－219 bp with respect to +1) led us to investigate the effect of this polymorphism on IL4 promoter activity.
('The', 'The', 'DT', 'B-NP', 'O')
('strong', 'strong', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('rs2243250T＞C', 'rs2243250T＞C', 'NN', 'B-NP', 'B-protein')
('with', 'with', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
('close', 'close', 'JJ', 'I-NP', 'O')
('proximity', 'proximity', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('transcription', 'transcription', 'NN', 'I-NP', 'O')
('initiation', 'initiation', 'NN', 'I-NP', 'O')
('site', 'site', 'NN', 'I-NP', 'O')
('(－219', '(－219', 'CD', 'I-NP', 'O')
('bp', 'bp', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('respect', 'respect', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('+1)', '+1)', 'NN', 'B-NP', 'O')
('led', 'lead', 'VBD', 'B-VP', 'O')
('us', 'us', 'PRP', 'B-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('investigate', 'investigate', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('effect', 'effect', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('polymorphism', 'polymorphism', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-DNA')
('promoter', 'promoter', 'NN', 'I-NP', 'I-DNA')
('activity.', 'activity.', 'NN', 'I-NP', 'O')
Results from searches for transcription factor binding sites (TFBS) suggested that rs2243250 C allele to T allele alteration would generate a SOX5 (SRY (sex determining region Y) box 5) binding site in the proximal promoter region of the gene.
('Results', 'Result', 'NNS', 'B-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('searches', 'search', 'NNS', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('transcription', 'transcription', 'NN', 'B-NP', 'B-protein')
('factor', 'factor', 'NN', 'I-NP', 'I-protein')
('binding', 'binding', 'NN', 'I-NP', 'O')
('sites', 'site', 'NNS', 'I-NP', 'O')
('(TFBS)', '(TFBS)', 'NN', 'I-NP', 'B-protein')
('suggested', 'suggest', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('rs2243250', 'rs2243250', 'NN', 'B-NP', 'B-DNA')
('C', 'C', 'NN', 'I-NP', 'I-DNA')
('allele', 'allele', 'NN', 'I-NP', 'I-DNA')
('to', 'to', 'TO', 'B-PP', 'O')
('T', 'T', 'NN', 'B-NP', 'O')
('allele', 'allele', 'NN', 'I-NP', 'O')
('alteration', 'alteration', 'NN', 'I-NP', 'O')
('would', 'would', 'MD', 'B-VP', 'O')
('generate', 'generate', 'VB', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('SOX5', 'SOX5', 'NN', 'I-NP', 'B-DNA')
('(SRY', '(SRY', 'NN', 'I-NP', 'I-DNA')
('(sex', '(sex', 'NN', 'I-NP', 'I-DNA')
('determining', 'determine', 'VBG', 'B-VP', 'I-DNA')
('region', 'region', 'NN', 'B-NP', 'I-DNA')
('Y)', 'Y)', 'NN', 'I-NP', 'I-DNA')
('box', 'box', 'NN', 'I-NP', 'I-DNA')
('5)', '5)', 'CD', 'I-NP', 'I-DNA')
('binding', 'binding', 'NN', 'I-NP', 'I-DNA')
('site', 'site', 'NN', 'I-NP', 'I-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('proximal', 'proximal', 'JJ', 'I-NP', 'B-DNA')
('promoter', 'promoter', 'NN', 'I-NP', 'I-DNA')
('region', 'region', 'NN', 'I-NP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gene.', 'gene.', 'NN', 'I-NP', 'O')
To this end, we prepared reporter gene constructs carrying β-lactamasecoding sequences whose expression was controlled by the IL4 promoter region.
('To', 'To', 'TO', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('end,', 'end,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('prepared', 'prepare', 'VBD', 'B-VP', 'O')
('reporter', 'reporter', 'NN', 'B-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('constructs', 'construct', 'NNS', 'I-NP', 'I-DNA')
('carrying', 'carry', 'VBG', 'B-VP', 'O')
('β-lactamasecoding', 'β-lactamasecoding', 'JJ', 'B-NP', 'B-DNA')
('sequences', 'sequence', 'NNS', 'I-NP', 'I-DNA')
('whose', 'whose', 'WP$', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('controlled', 'control', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-DNA')
('promoter', 'promoter', 'NN', 'I-NP', 'I-DNA')
('region.', 'region.', 'NN', 'I-NP', 'O')
These reporter constructs were then used for transfection of cells to measure reporter gene expression.
('These', 'These', 'DT', 'B-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'B-DNA')
('constructs', 'construct', 'NNS', 'I-NP', 'I-DNA')
('were', 'be', 'VBD', 'B-VP', 'O')
('then', 'then', 'RB', 'I-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('transfection', 'transfection', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('cells', 'cell', 'NNS', 'B-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('measure', 'measure', 'VB', 'I-VP', 'O')
('reporter', 'reporter', 'NN', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('expression.', 'expression.', 'NN', 'I-NP', 'O')
As shown in Fig.
('As', 'As', 'IN', 'B-SBAR', 'O')
('shown', 'show', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Fig.', 'Fig.', 'NNP', 'B-NP', 'O')
1, the cells transiently expressing the T allelecarrying reporter gene showed greater reporter activity than those with the C allelecarrying construct, which was consistent with the TFBS prediction results.
('1,', '1,', '1,', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cells', 'cell', 'NNS', 'I-NP', 'O')
('transiently', 'transiently', 'RB', 'B-VP', 'O')
('expressing', 'express', 'VBG', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('T', 'T', 'NN', 'I-NP', 'B-DNA')
('allelecarrying', 'allelecarrye', 'VBG', 'B-VP', 'I-DNA')
('reporter', 'reporter', 'NN', 'B-NP', 'I-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('showed', 'show', 'VBD', 'B-VP', 'O')
('greater', 'great', 'JJR', 'B-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'O')
('activity', 'activity', 'NN', 'I-NP', 'O')
('than', 'than', 'IN', 'B-PP', 'O')
('those', 'those', 'DT', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('C', 'C', 'NN', 'I-NP', 'O')
('allelecarrying', 'allelecarrye', 'VBG', 'B-VP', 'O')
('construct,', 'construct,', 'NN', 'B-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('consistent', 'consistent', 'JJ', 'B-ADJP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('TFBS', 'TFBS', 'NN', 'I-NP', 'B-protein')
('prediction', 'prediction', 'NN', 'I-NP', 'O')
('results.', 'results.', 'NNS', 'I-NP', 'O')
The allelic differential expression was consistently observed in two different cell lines, SW872, a human adipocyte cell line and SNU398, a human hepatocellular carcinoma cell line, which excluded the possibility of cell linespecific indirect effects.
('The', 'The', 'DT', 'B-NP', 'O')
('allelic', 'allelic', 'JJ', 'I-NP', 'O')
('differential', 'differential', 'JJ', 'I-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('consistently', 'consistently', 'RB', 'I-VP', 'O')
('observed', 'observe', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('two', 'two', 'CD', 'B-NP', 'O')
('different', 'different', 'JJ', 'I-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('lines,', 'lines,', 'NN', 'I-NP', 'O')
('SW872,', 'SW872,', 'NN', 'I-NP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('human', 'human', 'JJ', 'I-NP', 'B-cell_line')
('adipocyte', 'adipocyte', 'NN', 'I-NP', 'I-cell_line')
('cell', 'cell', 'NN', 'I-NP', 'I-cell_line')
('line', 'line', 'NN', 'I-NP', 'I-cell_line')
('and', 'and', 'CC', 'O', 'O')
('SNU398,', 'SNU398,', 'NN', 'B-NP', 'B-protein')
('a', 'a', 'DT', 'B-NP', 'O')
('human', 'human', 'JJ', 'I-NP', 'O')
('hepatocellular', 'hepatocellular', 'JJ', 'I-NP', 'O')
('carcinoma', 'carcinoma', 'NN', 'I-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('line,', 'line,', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('excluded', 'exclude', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('possibility', 'possibility', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('cell', 'cell', 'NN', 'B-NP', 'O')
('linespecific', 'linespecific', 'JJ', 'I-NP', 'O')
('indirect', 'indirect', 'JJ', 'I-NP', 'O')
('effects.', 'effects.', 'NNS', 'I-NP', 'O')
This result suggests that the IL4 promoter variant rs2243250T＞C might affect the gene expression level by modulating promoter activity in the SNPcontaining region.
('This', 'This', 'DT', 'B-NP', 'O')
('result', 'result', 'NN', 'I-NP', 'O')
('suggests', 'suggest', 'VBZ', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-DNA')
('promoter', 'promoter', 'NN', 'I-NP', 'I-DNA')
('variant', 'variant', 'JJ', 'I-NP', 'O')
('rs2243250T＞C', 'rs2243250T＞C', 'NN', 'I-NP', 'O')
('might', 'might', 'MD', 'B-VP', 'O')
('affect', 'affect', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('level', 'level', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('modulating', 'modulate', 'VBG', 'B-VP', 'O')
('promoter', 'promoter', 'NN', 'B-NP', 'O')
('activity', 'activity', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNPcontaining', 'SNPcontaining', 'NNP', 'I-NP', 'O')
('region.', 'region.', 'NN', 'I-NP', 'O')
There is accumulating evidence indicating a critical role for subacute chronic inflammation in the pathogenesis of obesityrelated insulin resistance and T2DM (Corvera et al., 2006; Dandona et al., 2004; Dandona et al., 2005; Finegood, 2003; Genco et al., 2005; Mangge et al., 2004; Meerarani et al., 2007; WangCai, 2006; Weisberg et al., 2003).
('There', 'There', 'EX', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('accumulating', 'accumulate', 'VBG', 'I-VP', 'O')
('evidence', 'evidence', 'NN', 'B-NP', 'O')
('indicating', 'indicate', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('critical', 'critical', 'JJ', 'I-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('subacute', 'subacute', 'JJ', 'B-NP', 'O')
('chronic', 'chronic', 'JJ', 'I-NP', 'O')
('inflammation', 'inflammation', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('pathogenesis', 'pathogenesis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('obesityrelated', 'obesityrelated', 'JJ', 'B-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'O')
('resistance', 'resistance', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('T2DM', 'T2DM', 'NN', 'I-NP', 'O')
('(Corvera', '(Corvera', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2006;', '2006;', ':', 'O', 'O')
('Dandona', 'Dandona', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2004;', '2004;', ':', 'O', 'O')
('Dandona', 'Dandona', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2005;', '2005;', ':', 'O', 'O')
('Finegood,', 'Finegood,', 'NNP', 'B-NP', 'O')
('2003;', '2003;', ':', 'O', 'O')
('Genco', 'Genco', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'B-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2005;', '2005;', ':', 'O', 'O')
('Mangge', 'Mangge', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2004;', '2004;', ':', 'O', 'O')
('Meerarani', 'Meerarani', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2007;', '2007;', ':', 'O', 'O')
('WangCai,', 'WangCai,', 'NNP', 'B-NP', 'O')
('2006;', '2006;', ':', 'O', 'O')
('Weisberg', 'Weisberg', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2003).', '2003).', 'CD', 'B-NP', 'O')
In obesity, adipose tissues were shown to be infiltrated by macrophages, which may be a major source of locallyproduced proinflammatory cytokines (Weisberg et al., 2003).
('In', 'In', 'IN', 'B-PP', 'O')
('obesity,', 'obesity,', 'NN', 'B-NP', 'O')
('adipose', 'adipose', 'NN', 'I-NP', 'O')
('tissues', 'tissue', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('infiltrated', 'infiltrate', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('macrophages,', 'macrophages,', 'NN', 'B-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('may', 'may', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('major', 'major', 'JJ', 'I-NP', 'O')
('source', 'source', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('locallyproduced', 'locallyproduced', 'JJ', 'B-NP', 'O')
('proinflammatory', 'proinflammatory', 'JJ', 'I-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('(Weisberg', '(Weisberg', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2003).', '2003).', 'CD', 'B-NP', 'O')
Increased levels of TNFα and IL6 were shown to correlate with reduced insulin stimulated glucose uptake in obese and T2DM patients (Bastard et al., 2006; Katsuki et al., 1998; Kern et al., 2001; Mishima et al., 2001).
('Increased', 'Increase', 'VBN', 'B-NP', 'O')
('levels', 'level', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('TNFα', 'TNFα', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL6', 'IL6', 'NN', 'I-NP', 'B-protein')
('were', 'be', 'VBD', 'B-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('correlate', 'correlate', 'VB', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('reduced', 'reduce', 'VBN', 'B-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'B-protein')
('stimulated', 'stimulate', 'VBD', 'B-VP', 'O')
('glucose', 'glucose', 'NN', 'B-NP', 'O')
('uptake', 'uptake', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('obese', 'obese', 'JJ', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('T2DM', 'T2DM', 'NN', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('(Bastard', '(Bastard', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2006;', '2006;', ':', 'O', 'O')
('Katsuki', 'Katsuki', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'NNP', 'I-NP', 'O')
('1998;', '1998;', ':', 'O', 'O')
('Kern', 'Kern', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2001;', '2001;', ':', 'O', 'O')
('Mishima', 'Mishima', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2001).', '2001).', 'CD', 'B-NP', 'O')
As a homeostatic mechanism in the immuneinflammatory system, antiinflammatory agents including IGF 1, IL10, IL13 and IL4 reduce secretion of proinflammatory cytokines by macrophages and stimulate the production of various antiinflammatory molecules (Orino et al., 1992; Sone et al., 1992; Vannier et al., 1992).
('As', 'As', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('homeostatic', 'homeostatic', 'JJ', 'I-NP', 'O')
('mechanism', 'mechanism', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('immuneinflammatory', 'immuneinflammatory', 'JJ', 'I-NP', 'O')
('system,', 'system,', 'NN', 'I-NP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'I-NP', 'O')
('agents', 'agent', 'NNS', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('IGF', 'IGF', 'NN', 'B-NP', 'B-protein')
('1,', '1,', '1,', 'B-NP', 'O')
('IL10,', 'IL10,', 'NN', 'I-NP', 'B-protein')
('IL13', 'IL13', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('reduce', 'reduce', 'VBP', 'B-VP', 'O')
('secretion', 'secretion', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('proinflammatory', 'proinflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('by', 'by', 'IN', 'B-PP', 'O')
('macrophages', 'macrophage', 'NNS', 'B-NP', 'B-cell_type')
('and', 'and', 'CC', 'O', 'O')
('stimulate', 'stimulate', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('production', 'production', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'I-NP', 'B-protein')
('molecules', 'molecule', 'NNS', 'I-NP', 'I-protein')
('(Orino', '(Orino', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', ',', 'O', 'O')
('1992;', '1992;', 'CD', 'B-NP', 'O')
('Sone', 'Sone', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', ',', 'O', 'O')
('1992;', '1992;', 'CD', 'B-NP', 'O')
('Vannier', 'Vannier', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1992).', '1992).', 'CD', 'B-NP', 'O')
Several reports have demonstrated that suppression of inflammation by the antiinflammatory cytokines is impaired in T2DM patients (O'Connor et al., 2007).
('Several', 'Several', 'JJ', 'B-NP', 'O')
('reports', 'report', 'NNS', 'I-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('demonstrated', 'demonstrate', 'VBN', 'I-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('suppression', 'suppression', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('inflammation', 'inflammation', 'NN', 'B-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'I-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('impaired', 'impaired', 'JJ', 'B-ADJP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
("(O'Connor", "(O'Connor", 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2007).', '2007).', 'CD', 'B-NP', 'O')
Insulin resistance due to obesityrelated chronic inflammation has been suggested as an underlying mechanism linking antiinflammatory cytokine dysfunction to T2DM (Shoelson et al., 2007).
('Insulin', 'Insulin', 'NN', 'B-NP', 'B-protein')
('resistance', 'resistance', 'NN', 'I-NP', 'O')
('due', 'due', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('obesityrelated', 'obesityrelated', 'JJ', 'B-NP', 'O')
('chronic', 'chronic', 'JJ', 'I-NP', 'O')
('inflammation', 'inflammation', 'NN', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('suggested', 'suggest', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('underlying', 'underlie', 'VBG', 'I-NP', 'O')
('mechanism', 'mechanism', 'NN', 'I-NP', 'O')
('linking', 'link', 'VBG', 'B-VP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokine', 'cytokine', 'NN', 'I-NP', 'I-protein')
('dysfunction', 'dysfunction', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('(Shoelson', '(Shoelson', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2007).', '2007).', 'CD', 'B-NP', 'O')
IL4, an antiinflammatory cytokine, is known to direct macrophages toward an 'alternatively activated' state that is characterized by low expression patterns of pro inflammatory cytokines and high levels of antiinflammatory cytokines (Gordon, 2003).
('IL4,', 'IL4,', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'I-NP', 'O')
('cytokine,', 'cytokine,', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('known', 'know', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('direct', 'direct', 'JJ', 'B-NP', 'B-cell_type')
('macrophages', 'macrophage', 'NNS', 'I-NP', 'I-cell_type')
('toward', 'toward', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
("'alternatively", "'alternatively", 'RB', 'I-NP', 'O')
("activated'", "activated'", 'JJ', 'I-NP', 'O')
('state', 'state', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('characterized', 'characterize', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('low', 'low', 'JJ', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('patterns', 'pattern', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('pro', 'pro', 'JJ', 'B-NP', 'B-protein')
('inflammatory', 'inflammatory', 'JJ', 'I-NP', 'I-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('high', 'high', 'JJ', 'B-NP', 'O')
('levels', 'level', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'B-NP', 'B-protein')
('cytokines', 'cytokine', 'NNS', 'I-NP', 'I-protein')
('(Gordon,', '(Gordon,', 'IN', 'B-PP', 'O')
('2003).', '2003).', 'CD', 'B-NP', 'O')
Although its detailed mechanism is not as well defined as that of proinflammatory cytokines, IL4 has received much attention for its potential relationship to insulin resistance and   T2DM, as supported by an observation showing that there is an IL4-dependent insulin signaling pathway in macrophages, and the positive regulatory functions for other anti-inflammatory cytokine production mechanisms were impaired in db/db diabetic model mice (Hartman et al., 2004; O'Connor et al., 2007).
('Although', 'Although', 'IN', 'B-SBAR', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
('detailed', 'detailed', 'JJ', 'I-NP', 'O')
('mechanism', 'mechanism', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('not', 'not', 'RB', 'O', 'O')
('as', 'as', 'RB', 'O', 'O')
('well', 'well', 'RB', 'B-ADJP', 'O')
('defined', 'define', 'VBN', 'I-ADJP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('that', 'that', 'DT', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('proinflammatory', 'proinflammatory', 'JJ', 'B-NP', 'O')
('cytokines,', 'cytokines,', 'NN', 'I-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('has', 'have', 'VBZ', 'B-VP', 'O')
('received', 'receive', 'VBN', 'I-VP', 'O')
('much', 'much', 'JJ', 'B-NP', 'O')
('attention', 'attention', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
('potential', 'potential', 'JJ', 'I-NP', 'O')
('relationship', 'relationship', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('insulin', 'insulin', 'NN', 'B-NP', 'O')
('resistance', 'resistance', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('T2DM,', 'T2DM,', 'NN', 'I-NP', 'B-protein')
('as', 'as', 'IN', 'B-SBAR', 'O')
('supported', 'support', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('observation', 'observation', 'NN', 'I-NP', 'O')
('showing', 'show', 'VBG', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('there', 'there', 'EX', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('IL4-dependent', 'IL4-dependent', 'JJ', 'I-NP', 'B-protein')
('insulin', 'insulin', 'NN', 'I-NP', 'I-protein')
('signaling', 'signaling', 'NN', 'I-NP', 'O')
('pathway', 'pathway', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('macrophages,', 'macrophages,', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('positive', 'positive', 'JJ', 'I-NP', 'O')
('regulatory', 'regulatory', 'JJ', 'I-NP', 'O')
('functions', 'function', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('anti-inflammatory', 'anti-inflammatory', 'JJ', 'I-NP', 'B-protein')
('cytokine', 'cytokine', 'NN', 'I-NP', 'I-protein')
('production', 'production', 'NN', 'I-NP', 'O')
('mechanisms', 'mechanism', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('impaired', 'impair', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('db/db', 'db/db', 'NN', 'B-NP', 'O')
('diabetic', 'diabetic', 'JJ', 'I-NP', 'O')
('model', 'model', 'NN', 'I-NP', 'O')
('mice', 'mouse', 'NNS', 'I-NP', 'O')
('(Hartman', '(Hartman', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2004;', '2004;', ':', 'O', 'O')
("O'Connor", "O'Connor", 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2007).', '2007).', 'CD', 'B-NP', 'O')
Moreover, a recent study clearly demonstrated that knockout mice defective in the IL4-stimulated alternative activation of macrophage were more susceptible to obesity and insulin resistance than were control mice (Odegaard et al., 2007).
('Moreover,', 'Moreover,', 'JJR', 'B-NP', 'O')
('a', 'a', 'DT', 'I-NP', 'O')
('recent', 'recent', 'JJ', 'I-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('clearly', 'clearly', 'RB', 'B-ADVP', 'O')
('demonstrated', 'demonstrate', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('knockout', 'knockout', 'JJ', 'B-NP', 'O')
('mice', 'mouse', 'NNS', 'I-NP', 'O')
('defective', 'defective', 'JJ', 'B-ADJP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4-stimulated', 'IL4-stimulated', 'JJ', 'I-NP', 'O')
('alternative', 'alternative', 'JJ', 'I-NP', 'O')
('activation', 'activation', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('macrophage', 'macrophage', 'NN', 'B-NP', 'B-cell_type')
('were', 'be', 'VBD', 'B-VP', 'O')
('more', 'more', 'RBR', 'B-ADJP', 'O')
('susceptible', 'susceptible', 'JJ', 'I-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('obesity', 'obesity', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'O')
('resistance', 'resistance', 'NN', 'I-NP', 'O')
('than', 'than', 'IN', 'B-SBAR', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('control', 'control', 'NN', 'B-NP', 'O')
('mice', 'mouse', 'NNS', 'I-NP', 'O')
('(Odegaard', '(Odegaard', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2007).', '2007).', 'CD', 'B-NP', 'O')
These previous results prompted us to investigate whether genetic polymorphisms of the IL4 and IL4 receptor-coding genes would modulate host susceptibility to T2DM.
('These', 'These', 'DT', 'B-NP', 'O')
('previous', 'previous', 'JJ', 'I-NP', 'O')
('results', 'result', 'NNS', 'I-NP', 'O')
('prompted', 'prompt', 'VBD', 'B-VP', 'O')
('us', 'us', 'PRP', 'B-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('investigate', 'investigate', 'VB', 'I-VP', 'O')
('whether', 'whether', 'IN', 'B-SBAR', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('receptor-coding', 'receptor-coding', 'JJ', 'I-NP', 'O')
('genes', 'gene', 'NNS', 'I-NP', 'O')
('would', 'would', 'MD', 'B-VP', 'O')
('modulate', 'modulate', 'VB', 'I-VP', 'O')
('host', 'host', 'NN', 'B-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('T2DM.', 'T2DM.', 'NN', 'B-NP', 'O')
Although there have been several reports controversially linking IL4 and IL4R polymorphisms to risk for autoimmune T1DM in various ethnic backgrounds, there have been no reports such an association with T2DM (Bugawan et al., 2003; Maier et al., 2005; Nunez et al., 2008; Reimsnider et al., 2000).
('Although', 'Although', 'IN', 'B-SBAR', 'O')
('there', 'there', 'EX', 'B-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('several', 'several', 'JJ', 'B-NP', 'O')
('reports', 'report', 'NNS', 'I-NP', 'O')
('controversially', 'controversially', 'RB', 'B-VP', 'O')
('linking', 'link', 'VBG', 'I-VP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4R', 'IL4R', 'NN', 'I-NP', 'B-protein')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('risk', 'risk', 'VB', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('autoimmune', 'autoimmune', 'JJ', 'B-NP', 'O')
('T1DM', 'T1DM', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('backgrounds,', 'backgrounds,', 'NN', 'I-NP', 'O')
('there', 'there', 'EX', 'B-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('reports', 'report', 'NNS', 'I-NP', 'O')
('such', 'such', 'PDT', 'B-NP', 'O')
('an', 'an', 'DT', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('(Bugawan', '(Bugawan', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2003;', '2003;', ':', 'O', 'O')
('Maier', 'Maier', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2005;', '2005;', ':', 'O', 'O')
('Nunez', 'Nunez', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2008;', '2008;', ':', 'O', 'O')
('Reimsnider', 'Reimsnider', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2000).', '2000).', 'CD', 'B-NP', 'O')
In this report, we present results from two-stage case-control association and functional analyses showing that a SNP located in the IL4 promoter region, rs2243250T＞C, is associated with the risk of T2DM.
('In', 'In', 'IN', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('report,', 'report,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('present', 'present', 'VBP', 'B-VP', 'O')
('results', 'result', 'NNS', 'B-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('two-stage', 'two-stage', 'JJ', 'B-NP', 'O')
('case-control', 'case-control', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('functional', 'functional', 'JJ', 'B-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('showing', 'show', 'VBG', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('SNP', 'SNP', 'NN', 'I-NP', 'B-protein')
('located', 'locate', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-DNA')
('promoter', 'promoter', 'NN', 'I-NP', 'I-DNA')
('region,', 'region,', 'NN', 'I-NP', 'O')
('rs2243250T＞C,', 'rs2243250T＞C,', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('T2DM.', 'T2DM.', 'NN', 'B-NP', 'O')
Although we found no association of any of the common IL4RA SNP with disease susceptibility in our study population, we observed association between intronic variants of IL4RA and obesity-related BMI and insulin level.
('Although', 'Although', 'IN', 'B-SBAR', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('found', 'find', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('any', 'any', 'DT', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('common', 'common', 'JJ', 'I-NP', 'O')
('IL4RA', 'IL4RA', 'NN', 'I-NP', 'B-protein')
('SNP', 'SNP', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('disease', 'disease', 'NN', 'B-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('population,', 'population,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('observed', 'observe', 'VBD', 'B-VP', 'O')
('association', 'association', 'NN', 'B-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('intronic', 'intronic', 'JJ', 'B-NP', 'O')
('variants', 'variant', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4RA', 'IL4RA', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('obesity-related', 'obesity-related', 'JJ', 'I-NP', 'O')
('BMI', 'BMI', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'O')
('level.', 'level.', 'NN', 'I-NP', 'O')
Moreover, our gene-gene-interaction analyses implied that this functional IL4 promoter SNP could modify disease susceptibility in combination with the intronic SNP in the IL4RA gene.
('Moreover,', 'Moreover,', 'JJR', 'B-NP', 'O')
('our', 'our', 'PRP$', 'I-NP', 'O')
('gene-gene-interaction', 'gene-gene-interaction', 'NN', 'I-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('implied', 'imply', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('functional', 'functional', 'JJ', 'I-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'O')
('promoter', 'promoter', 'NN', 'I-NP', 'O')
('SNP', 'SNP', 'NN', 'I-NP', 'O')
('could', 'could', 'MD', 'B-VP', 'O')
('modify', 'modify', 'VB', 'I-VP', 'O')
('disease', 'disease', 'NN', 'B-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('combination', 'combination', 'NN', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('intronic', 'intronic', 'JJ', 'I-NP', 'B-DNA')
('SNP', 'SNP', 'NN', 'I-NP', 'I-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('IL4RA', 'IL4RA', 'NN', 'I-NP', 'B-protein')
('gene.', 'gene.', 'NN', 'I-NP', 'O')
Our reporter gene expression assay indicates that rs2243250T＞C may affect the overall IL4 promoter activity modulating the gene expression level.
('Our', 'Our', 'PRP$', 'B-NP', 'O')
('reporter', 'reporter', 'NN', 'I-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('expression', 'expression', 'NN', 'I-NP', 'O')
('assay', 'assay', 'NN', 'I-NP', 'O')
('indicates', 'indicate', 'VBZ', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('rs2243250T＞C', 'rs2243250T＞C', 'NN', 'B-NP', 'O')
('may', 'may', 'MD', 'B-VP', 'O')
('affect', 'affect', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('overall', 'overall', 'JJ', 'I-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-DNA')
('promoter', 'promoter', 'NN', 'I-NP', 'I-DNA')
('activity', 'activity', 'NN', 'I-NP', 'O')
('modulating', 'modulate', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('level.', 'level.', 'NN', 'I-NP', 'O')
The minor C allele, which is associated with a decreased risk of T2DM, was shown to lower the expression level.
('The', 'The', 'DT', 'B-NP', 'O')
('minor', 'minor', 'JJ', 'I-NP', 'O')
('C', 'C', 'NN', 'I-NP', 'O')
('allele,', 'allele,', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('decreased', 'decrease', 'VBN', 'I-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('T2DM,', 'T2DM,', 'NN', 'B-NP', 'B-protein')
('was', 'be', 'VBD', 'B-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('lower', 'lower', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('level.', 'level.', 'NN', 'I-NP', 'O')
This functional consequence of the protective allele reducing IL4 expression was unexpected, given the previous reports showing links between impaired IL4 function in diabetic model animals and obesity and insulin resistance (Hartman et al., 2004; O'Connor et al., 2007).
('This', 'This', 'DT', 'B-NP', 'O')
('functional', 'functional', 'JJ', 'I-NP', 'O')
('consequence', 'consequence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('protective', 'protective', 'JJ', 'I-NP', 'B-DNA')
('allele', 'allele', 'NN', 'I-NP', 'I-DNA')
('reducing', 'reduce', 'VBG', 'B-VP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('expression', 'expression', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('unexpected,', 'unexpected,', 'JJ', 'B-ADJP', 'O')
('given', 'give', 'VBN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('previous', 'previous', 'JJ', 'I-NP', 'O')
('reports', 'report', 'NNS', 'I-NP', 'O')
('showing', 'show', 'VBG', 'B-VP', 'O')
('links', 'link', 'NNS', 'B-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('impaired', 'impaired', 'JJ', 'B-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('function', 'function', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('diabetic', 'diabetic', 'JJ', 'B-NP', 'O')
('model', 'model', 'NN', 'I-NP', 'O')
('animals', 'animal', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('obesity', 'obesity', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('insulin', 'insulin', 'NN', 'I-NP', 'B-protein')
('resistance', 'resistance', 'NN', 'I-NP', 'I-protein')
('(Hartman', '(Hartman', 'NNP', 'I-NP', 'I-protein')
('et', 'et', 'NNP', 'I-NP', 'I-protein')
('al.,', 'al.,', 'VBD', 'B-VP', 'I-protein')
('2004;', '2004;', ':', 'O', 'I-protein')
("O'Connor", "O'Connor", 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2007).', '2007).', 'CD', 'B-NP', 'O')
A possible explanation for our result is the presence of other interacting genetic and/or environmental effects involved in IL4 function, other than the expression level itself.
('A', 'A', 'DT', 'B-NP', 'O')
('possible', 'possible', 'JJ', 'I-NP', 'O')
('explanation', 'explanation', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('result', 'result', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('presence', 'presence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('interacting', 'interact', 'VBG', 'I-NP', 'O')
('genetic', 'genetic', 'JJ', 'I-NP', 'O')
('and/or', 'and/or', 'CC', 'I-NP', 'O')
('environmental', 'environmental', 'JJ', 'I-NP', 'O')
('effects', 'effect', 'NNS', 'I-NP', 'O')
('involved', 'involve', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-protein')
('function,', 'function,', 'NN', 'I-NP', 'O')
('other', 'other', 'JJ', 'B-ADJP', 'O')
('than', 'than', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('level', 'level', 'NN', 'I-NP', 'O')
('itself.', 'itself.', 'PRP$', 'B-NP', 'O')
It could include additional mechanisms by which increased expression levels of IL4 receptor coding gene and/or other anti-inflammatory cytokine genes would compensate for the decreased IL4 expression level.
('It', 'It', 'PRP', 'B-NP', 'O')
('could', 'could', 'MD', 'B-VP', 'O')
('include', 'include', 'VB', 'I-VP', 'O')
('additional', 'additional', 'JJ', 'B-NP', 'O')
('mechanisms', 'mechanism', 'NNS', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('increased', 'increase', 'VBD', 'B-VP', 'O')
('expression', 'expression', 'NN', 'B-NP', 'O')
('levels', 'level', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IL4', 'IL4', 'NN', 'B-NP', 'B-DNA')
('receptor', 'receptor', 'NN', 'I-NP', 'I-DNA')
('coding', 'coding', 'NN', 'I-NP', 'I-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('and/or', 'and/or', 'CC', 'O', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('anti-inflammatory', 'anti-inflammatory', 'JJ', 'I-NP', 'B-DNA')
('cytokine', 'cytokine', 'NN', 'I-NP', 'I-DNA')
('genes', 'gene', 'NNS', 'I-NP', 'I-DNA')
('would', 'would', 'MD', 'B-VP', 'O')
('compensate', 'compensate', 'VB', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('decreased', 'decrease', 'VBN', 'I-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('expression', 'expression', 'NN', 'I-NP', 'O')
('level.', 'level.', 'NN', 'I-NP', 'O')
Additional in-depth functional and physiological studies will be needed to establish the mechanism of this association.
('Additional', 'Additional', 'JJ', 'B-NP', 'O')
('in-depth', 'in-depth', 'JJ', 'I-NP', 'O')
('functional', 'functional', 'JJ', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('physiological', 'physiological', 'JJ', 'I-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('will', 'will', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('needed', 'need', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('establish', 'establish', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mechanism', 'mechanism', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('association.', 'association.', 'NN', 'I-NP', 'O')
On the basis of our findings, as well as the functional data of other groups, we propose that the genetic polymorphisms of an antiinflammatory cytokine coding IL4 and IL4RA may modify an individual's susceptibility to T2DM.
('On', 'On', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('basis', 'basis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('findings,', 'findings,', 'NN', 'I-NP', 'O')
('as', 'as', 'RB', 'B-CONJP', 'O')
('well', 'well', 'RB', 'I-CONJP', 'O')
('as', 'as', 'IN', 'I-CONJP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('functional', 'functional', 'JJ', 'I-NP', 'O')
('data', 'datum', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('groups,', 'groups,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('propose', 'propose', 'VBP', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genetic', 'genetic', 'JJ', 'I-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('antiinflammatory', 'antiinflammatory', 'JJ', 'I-NP', 'O')
('cytokine', 'cytokine', 'NN', 'I-NP', 'O')
('coding', 'coding', 'NN', 'I-NP', 'O')
('IL4', 'IL4', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IL4RA', 'IL4RA', 'NN', 'I-NP', 'B-protein')
('may', 'may', 'MD', 'B-VP', 'O')
('modify', 'modify', 'VB', 'I-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
("individual's", "individual'", 'NNS', 'I-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('T2DM.', 'T2DM.', 'NN', 'B-NP', 'O')
Despite the recent success of GWAS in identifying T2DM susceptibility loci, our findings have shown that a hypothesisbased candidate gene approach which complements GWAS is still a powerful way to identify unknown diseaseassociated loci.
('Despite', 'Despite', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('recent', 'recent', 'JJ', 'I-NP', 'O')
('success', 'success', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('GWAS', 'GWAS', 'NN', 'B-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('identifying', 'identify', 'VBG', 'B-VP', 'O')
('T2DM', 'T2DM', 'NN', 'B-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('loci,', 'loci,', 'IN', 'B-PP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('findings', 'finding', 'NNS', 'I-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('hypothesisbased', 'hypothesisbased', 'JJ', 'I-NP', 'O')
('candidate', 'candidate', 'NN', 'I-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('approach', 'approach', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('complements', 'complement', 'VBZ', 'B-VP', 'O')
('GWAS', 'GWAS', 'NN', 'B-NP', 'B-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('still', 'still', 'RB', 'B-ADVP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('powerful', 'powerful', 'JJ', 'I-NP', 'O')
('way', 'way', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('identify', 'identify', 'VB', 'I-VP', 'O')
('unknown', 'unknown', 'JJ', 'B-NP', 'O')
('diseaseassociated', 'diseaseassociated', 'JJ', 'I-NP', 'O')
('loci.', 'loci.', 'NN', 'I-NP', 'O')
We believe our findings contribute to a better understanding of the disease etiology and may help to identify unknown genes in the relevant pathways or mechanism.
('We', 'We', 'PRP', 'B-NP', 'O')
('believe', 'believe', 'VBP', 'B-VP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('findings', 'finding', 'NNS', 'I-NP', 'O')
('contribute', 'contribute', 'VBP', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('better', 'good', 'JJR', 'I-NP', 'O')
('understanding', 'understanding', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('disease', 'disease', 'NN', 'I-NP', 'O')
('etiology', 'etiology', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('may', 'may', 'MD', 'B-VP', 'O')
('help', 'help', 'VB', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('identify', 'identify', 'VB', 'I-VP', 'O')
('unknown', 'unknown', 'JJ', 'B-NP', 'O')
('genes', 'gene', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('relevant', 'relevant', 'JJ', 'I-NP', 'O')
('pathways', 'pathway', 'NNS', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('mechanism.', 'mechanism.', 'NN', 'B-NP', 'O')
Supplementary data including a figure and two tables can be found with this article online at http://www.
('Supplementary', 'Supplementary', 'JJ', 'B-NP', 'O')
('data', 'datum', 'NNS', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('figure', 'figure', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('two', 'two', 'CD', 'B-NP', 'O')
('tables', 'table', 'NNS', 'I-NP', 'O')
('can', 'can', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('found', 'find', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('article', 'article', 'NN', 'I-NP', 'O')
('online', 'online', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('http://www.', 'http://www.', 'NN', 'B-NP', 'O')
genominfo.
('genominfo.', 'genominfo.', 'LS', 'B-LST', 'O')
org/html/UploadFile/article3_2011306_SP.
('org/html/UploadFile/article3_2011306_SP.', 'org/html/UploadFile/article3_2011306_SP.', 'NN', 'B-NP', 'O')
pdf.
('pdf.', 'pdf.', 'LS', 'B-LST', 'O')
